var title_f36_47_37616="Straight leg raise";
var content_f36_47_37616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Straight leg raise maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The straight leg raise maneuver is used to determine the presence of radiculopathy. The maneuver can be performed in the sitting or lying position. The leg is gradually moved to the fully extended position. Ankle dorsiflexion can be added in full extension to bring out subtle cases. A positive maneuver reproduces the patient's pain; the test is inconclusive if tightness or pain is felt only in the hamstring area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37616=[""].join("\n");
var outline_f36_47_37616=null;
var title_f36_47_37617="Patient information: Hives (The Basics)";
var content_f36_47_37617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15456\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/41/7824\">",
"         Hives",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/17/18706\">",
"         Patient information: Chronic hives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/27/44466\">",
"         Patient information: Physical hives (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/45/2772\">",
"         Patient information: Hives (urticaria) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hives (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hives-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H478574267\">",
"      <span class=\"h1\">",
"       What are hives?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hives are raised, red patches of skin that are usually very itchy (",
"      <a class=\"graphic graphic_picture graphicRef79242 \" href=\"mobipreview.htm?7/41/7824\">",
"       picture 1",
"      </a>",
"      ). They can happen because of an allergy or other causes. In most cases, hives come and go within a few hours. But they can show up again and again in some people.",
"     </p>",
"     <p>",
"      Some people who get hives also get a condition called &ldquo;angioedema.&rdquo; Angioedema usually causes puffiness of the face, eyelids, ears, mouth, hands, feet, and genitals.",
"     </p>",
"     <p>",
"      Some people who get hives or angioedema are having a dangerous allergic reaction.",
"      <strong>",
"       See a doctor or nurse right away",
"      </strong>",
"      if you suddenly get hives or get puffy and also have any of these symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Tightness in the throat",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Cramps or stomach pain",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478574274\">",
"      <span class=\"h1\">",
"       Why did I get hives?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you just got hives for the first time, you might have a new allergy to something. People can get hives because of allergies to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines, such as antibiotics or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"       </li>",
"       <li>",
"        Something they touched, such as a plant, animal saliva, or latex",
"       </li>",
"       <li>",
"        Insect stings",
"       </li>",
"       <li>",
"        Foods, such as eggs, nuts, fish, or shellfish",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your hives are caused by an allergy, you may need to avoid whatever you are allergic to.",
"     </p>",
"     <p>",
"      Hives can also be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Infections",
"       </li>",
"       <li>",
"        Having cold air or water on the skin",
"       </li>",
"       <li>",
"        Having something press or vibrate against the skin",
"       </li>",
"       <li>",
"        Changes in body temperature (such as when you cool down after a hot shower or a work out)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have had hives on most days for more than 6 weeks, you probably do not have an allergy. Hives that last this long are called &ldquo;chronic hives.&rdquo; In most cases, doctors do not know what causes chronic hives.",
"     </p>",
"     <p>",
"      If you have chronic hives, you will probably need to take medicines every day to control them. Luckily, chronic hives do usually go away with time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478574281\">",
"      <span class=\"h1\">",
"       How are hives treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You may not need treatment. Hives usually go away in a few days or weeks, even if you do not get treated. But if you do need treatment, the first step is to figure out if anything triggered the hives. If so, you will need to avoid that trigger.",
"     </p>",
"     <p>",
"      To relieve itching, you can take medicines called antihistamines. These are the same medicines people usually take for allergies.",
"     </p>",
"     <p>",
"      If you have severe hives or your hives will not go away, your doctor or nurse might suggest that you take medicines called steroids for a short time. Steroids work well but you should not take them for long, because they can cause serious side effects. These steroids are not the same ones that athletes take to build up muscle. These steroids relieve itching and reduce swelling.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478574288\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18706?source=see_link\">",
"       Patient information: Chronic hives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/27/44466?source=see_link\">",
"       Patient information: Physical hives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/45/2772?source=see_link\">",
"       Patient information: Hives (urticaria) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/47/37617?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15456 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37617=[""].join("\n");
var outline_f36_47_37617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478574267\">",
"      What are hives?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478574274\">",
"      Why did I get hives?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478574281\">",
"      How are hives treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478574288\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/41/7824\">",
"      Hives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18706?source=related_link\">",
"      Patient information: Chronic hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/45/2772?source=related_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/27/44466?source=related_link\">",
"      Patient information: Physical hives (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37618="Technetium Tc-99m tetrofosmin: Drug information";
var content_f36_47_37618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m tetrofosmin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/51/4915?source=see_link\">",
"    see \"Technetium Tc-99m tetrofosmin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15516542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myoview&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15245908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15245985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Myocardial imaging:",
"     </b>",
"     I.V.: Dosage range: 5-33 mCi (185-1221 MBq). When rest and stress imaging are performed on the same day, administer a first dose of 5-12 mCi (185-444 MBq) followed by a second dose of 15-33 mCi (555-1221 MBq) ~1-4 hours later.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15245999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15516543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myoview&trade;: Tetrofosmin 0.23 mg (5s) [vial contents to be combined with sodium pertechnetate Tc99m (not included)]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15246000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Not for direct I.V. injection; only reconstituted technetium Tc 99m tetrofosmin may be administered I.V. Waterproof gloves should be worn while handling and administering technetium Tc 99m tetrofosmin. See manufacturer&rsquo;s prescribing information for complete administration procedure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15245910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Scintigraphic evaluation of the myocardium in conjunction with exercise stress testing or pharmacologic stress testing to identify reversible myocardial ischemia with or without myocardial infarction; evaluation of left ventricular ejection fraction and wall motion",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15245942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Hematologic: Leukocytosis (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, angina, cutaneous allergy, dyspnea, hypertension, hypotension, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15245922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15245923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"     <b>",
"      Note:",
"     </b>",
"     Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Coronary artery disease: Patients with known or suspected coronary artery disease should undergo continuous cardiac monitoring during diagnostic evaluation with technetium Tc 99m tetrofosmin; emergency cardiac treatment should be immediately available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 4-6 hours following administration to decrease radiation exposure to the bladder.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15594483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15594481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15245911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15245912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15245913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15245917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Technetium Tc 99m tetrofosmin is excreted in breast milk. The manufacturer recommends that formula feedings be substituted until radioactivity has cleared.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15245960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributed in the myocardium, blood, liver, and lung",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Physical half-life: 6.03 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Myocardium uptake: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (40% of injected activity within 48 hours); feces (26% of injected activity within 48 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86873 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37618=[""].join("\n");
var outline_f36_47_37618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15516542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245908\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245985\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245999\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15516543\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15246000\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245910\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245904\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245942\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245922\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245923\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594483\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594481\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245912\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245913\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245917\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245960\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86873|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/51/4915?source=related_link\">",
"      Technetium Tc-99m tetrofosmin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37619="Atrophy breast tissue menopause";
var content_f36_47_37619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Atrophy of breast tissue in menopause",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A section of breast tissue from a postmenopausal woman demonstrating atrophy of the glandular tissues. The stroma is composed primarily of adiopose tissue.",
"    <div class=\"footnotes\">",
"     A: lower lower view of an atrophic lobule; B: higher-power view of an atrophic lobule.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schnitt, SJ. Normal anatomy and development, In: Atlas of Breast Cancer, Hayes, DF (Ed). Harcourt Publishers Ltd. 2000, p.3.4. Copyright &copy; 2000 Mosby.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37619=[""].join("\n");
var outline_f36_47_37619=null;
var title_f36_47_37620="Cidofovir: An overview";
var content_f36_47_37620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cidofovir: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Martin Rodriguez, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37620/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/47/37620/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    was the first nucleotide analogue approved for clinical use. The drug has been employed almost exclusively to treat cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS). However, cidofovir is also being increasingly used as a therapeutic option against other viral infections.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    is a monophosphate nucleotide analogue. After undergoing cellular phosphorylation to its diphosphate form, it competitively inhibits the incorporation of deoxycytidine triphosphate into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/1\">",
"     1",
"    </a>",
"    ]. Unlike nucleoside analogues such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , cidofovir is not phosphorylated (and hence activated) by a viral kinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    demonstrates in vitro activity against a number of DNA viruses, including the herpesviruses, adenovirus, polyomavirus, papillomavirus, and poxvirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/2\">",
"     2",
"    </a>",
"    ]. Cidofovir also retains activity against thymidine kinase-negative herpes simplex virus (HSV) and UL97 phosphotransferase-negative CMV, which are mutant viruses resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . Clinical efficacy has been demonstrated rigorously only against CMV. Its clinical utility in infections caused by other viral pathogens remains to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced susceptibility of CMV to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    has been associated with mutations in the viral DNA polymerase gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Since its mechanism of action does not require phosphorylation, cidofovir is unaffected by mutations in CMV phosphotransferase which confer resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . However, prolonged therapy with ganciclovir in patients with CMV retinitis has been associated with the emergence of viral DNA polymerase mutations which confer cross resistance to cidofovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BASIC PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) yields peak plasma concentrations of 7.3 to 11.5",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Over 80 percent of the drug is excreted unchanged in the urine within 24 hours, with a half-life of 2.4 to 3.2 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/1\">",
"     1",
"    </a>",
"    ]. However, cidofovir diphosphate, an active metabolite is eliminated more slowly with first and second phase intracellular half-lives of 24 and 65 hours, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/1\">",
"     1",
"    </a>",
"    ]. This property permits the drug to be dosed every two weeks.",
"   </p>",
"   <p>",
"    The most important toxicity of the drug is renal which can be reduced by coadministration with saline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ; probenecid blocks active renal tubular secretion (see below). Dosing probenecid prior to, two hours after, and eight hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    infusion may result in the doubling of serum concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/1\">",
"     1",
"    </a>",
"    ]. The fact that probenecid protects against nephrotoxicity and yet decreases renal clearance of the drug, may seem paradoxical. However, the drug appears to prevent damage to proximal renal tubular epithelial cells by preventing the uptake of cidofovir into these cells; at the same time, drug concentrations can decrease more slowly since these same renal cells are responsible for secreting the drug into the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the most important toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    is dose dependent nephrotoxicity; the drug is contraindicated in persons with proteinuria (2+ or greater) or baseline serum creatinine greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Cidofovir has been associated with decreased renal function and the emergence of a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Serum creatinine and urine protein (dipstick is acceptable) should be checked within 48 hours prior to each dose of cidofovir, and dose reduction or discontinuation is required for evidence of renal dysfunction. Approximately 50 percent of patients receiving cidofovir in clinical trials developed either proteinuria (2+ or greater), increased serum creatinine (rise of at least 0.4",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or decreased creatinine clearance (55",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or less) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal dysfunction is usually reversible with discontinuation of the drug. However, a few cases of end-stage renal disease associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    in HIV-positive individuals have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Topical or intralesional use of cidofovir may also be rarely associated with renal dysfunction and monitoring may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The systemic absorption of cidofovir after topical application is probably higher if applied to non-intact skin.",
"   </p>",
"   <p>",
"    Patients should receive one liter of normal saline over one to two hours immediately preceding the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    dose and, if they can tolerate the fluid load, a second liter either during or immediately following the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients must also receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    (2 g PO 3h prior and 1 g 2 and 8h following cidofovir) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea and vomiting are common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    and may be reduced by giving the drug with food or by administration of antiemetics. Rash is also common and management with an antihistamine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenia has been observed in approximately 20 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ]; it is more difficult to establish causality for this finding given its common appearance in advanced AIDS. In rats, cidofovir has been associated with mammary adenocarcinoma and thus it should be regarded as a potential human carcinogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute iritis and ocular hypotony, which have precluded intravitreal administration, have also been associated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, when evaluating a patient with ocular inflammation who is receiving both cidofovir for CMV retinitis and highly active antiretroviral therapy (HAART) one must also consider the possibility of vitritis associated with immune system recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has been assigned to Pregnancy Category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). It is embryotoxic in rats and rabbits, and there are no adequate studies in pregnant women. Women of childbearing potential should use contraception during and for one month following treatment with cidofovir, and men who have sex with women of childbearing potential should use barrier contraception during and for three months after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37620/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    should be used in pregnant women only if the potential benefits outweigh the risk to the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL USE OF CIDOFOVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has only been rigorously studied in AIDS patients for treatment of CMV retinitis. The management of AIDS patients with CMV retinitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13337?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\", section on 'Cidofovir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidance on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    for other potential indications (eg, treatment of drug-resistance genital herpes simplex virus infection) is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=see_link&amp;anchor=H3087553#H3087553\">",
"     \"Monkeypox\", section on 'Cidofovir'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=see_link&amp;anchor=H28#H28\">",
"     \"Vaccinia virus as the smallpox vaccine\", section on 'Other drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis and treatment of adenovirus infection\", section on 'Cidofovir'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34024?source=see_link&amp;anchor=H28740855#H28740855\">",
"     \"Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients\", section on 'Topical therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1177297\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      is a monophosphate nucleotide analogue of deoxycytidine (dCTP). After undergoing cellular phosphorylation, cidofovir competitively inhibits the incorporation of dCTP into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      demonstrates in vitro activity against a number of DNA viruses, including adenovirus, polyomavirus, papillomavirus, poxvirus and the herpesviruses (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      -resistant strains of HSV). Clinical efficacy has been demonstrated rigorously only against cytomegalovirus infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduced susceptibility of cytomegalovirus to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      has been associated with mutations in the viral DNA polymerase gene. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over 80 percent of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      is excreted unchanged in the urine within 24 hours, with a half-life of 2.4 to 3.2 hours. However, its active metabolite is eliminated more slowly, which permits drug dosing every two weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important toxicity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      is dose-dependent nephrotoxicity; cidofovir has been associated with decreased renal function and the emergence of a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting. Cidofovir is contraindicated in persons with significant proteinuria or with a baseline serum creatinine greater than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should receive one liter of normal saline over one to two hours immediately preceding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      dosing. If they can tolerate the fluid load, a second liter should be given either during or immediately following cidofovir administration. Patients must also receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      (2 g PO 3 hours prior and 1 g 2 and 8 hours following cidofovir), which may prevent damage to proximal renal tubular epithelial cells by preventing the uptake of cidofovir into these cells. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      should be used in pregnant women only if the potential benefits outweigh the risk to the fetus. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Use in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/1\">",
"      Lea AP, Bryson HM. Cidofovir. Drugs 1996; 52:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/2\">",
"      De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/3\">",
"      Cherrington JM, Fuller MD, Lamy PD, et al. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J Infect Dis 1998; 178:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/4\">",
"      Erice A, Gil-Roda C, P&eacute;rez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/5\">",
"      Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/6\">",
"      Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/7\">",
"      Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689.",
"     </a>",
"    </li>",
"    <li>",
"     VISTIDE prescribing information. Gilead Sciences, Inc., 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/9\">",
"      Vittecoq D, Dumitrescu L, Beaufils H, Deray G. Fanconi syndrome associated with cidofovir therapy. Antimicrob Agents Chemother 1997; 41:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/10\">",
"      Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/11\">",
"      Meier P, Dautheville-Guibal S, Ronco PM, Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/12\">",
"      Naiman AN, Roger G, Gagnieu MC, et al. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 2004; 114:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/13\">",
"      Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/14\">",
"      Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37620/abstract/15\">",
"      Friedberg DN. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:801.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8297 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-118.97.94.19-03632C4B59-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37620=[""].join("\n");
var outline_f36_47_37620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1177297\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BASIC PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL USE OF CIDOFOVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1177297\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=related_link\">",
"      Monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13337?source=related_link\">",
"      Treatment of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34024?source=related_link\">",
"      Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37621="Rizatriptan: Patient drug information";
var content_f36_47_37621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rizatriptan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/14/29925?source=see_link\">",
"     see \"Rizatriptan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/24/8581?source=see_link\">",
"     see \"Rizatriptan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxalt-MLT&reg;;",
"     </li>",
"     <li>",
"      Maxalt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rizatriptan&reg;;",
"     </li>",
"     <li>",
"      CO Rizatriptan;",
"     </li>",
"     <li>",
"      CO Rizatriptan ODT;",
"     </li>",
"     <li>",
"      JAMP-Rizatriptan;",
"     </li>",
"     <li>",
"      Mar-Rizatriptan;",
"     </li>",
"     <li>",
"      Maxalt RPD&trade;;",
"     </li>",
"     <li>",
"      Maxalt&trade;;",
"     </li>",
"     <li>",
"      Mylan-Rizatriptan ODT;",
"     </li>",
"     <li>",
"      Sandoz-Rizatriptan ODT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rizatriptan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703466",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Some types of migraine headaches, chest pain or pressure, diseased arteries going to the legs, heart disease, poor bowel blood flow, stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug to stop you from getting migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken almotriptan, eletriptan, frovatriptan, naratriptan, sumatriptan, or zolmitriptan in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken ergotamine, methysergide, or dihydroergotamine in the last 24 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache or if headache is not better after the first dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow Maxalt&reg; tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with liquids as early as you can after the attack has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your headache comes back after the first dose, 1 more dose may be taken 2 hours after the first one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695516",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use Maxalt-MLT&reg; tablets right after opening.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11032 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-C984CE7589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37621=[""].join("\n");
var outline_f36_47_37621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017808\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017810\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017809\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017814\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017815\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017817\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017812\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017813\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017818\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017819\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/14/29925?source=related_link\">",
"      Rizatriptan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/24/8581?source=related_link\">",
"      Rizatriptan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37622="Reported cases of tularemia in US from 1990-2000";
var content_f36_47_37622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Map of reported cases* of tularemia in the United States, 1990-2000",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Number of cases of tularemia reported to the Center for Disease Control and Prevention (CDC) from 1990-2000 based on geographic location.",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Tularemia in the United States, 1990-2000. MMWR Morb Mortal Wkly Rep 2002; 51(9):181.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37622=[""].join("\n");
var outline_f36_47_37622=null;
var title_f36_47_37623="Preimplantation genetic screening (PGS) for aneuploidy";
var content_f36_47_37623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preimplantation genetic screening (PGS) for aneuploidy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37623/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37623/contributors\">",
"     Glenn L Schattman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37623/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37623/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37623/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/47/37623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H120198825\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of preimplantation genetic testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preimplantation genetic screening (PGS) is performed on oocytes or a blastomere obtained from a preimplantation embryo. The goal is to identify de-novo aneuploidy in embryo(s) of couples known or presumed to be chromosomally normal to allow selection of only those embryos with normal karyotypes for transfer. A high percentage of preimplantation embryos are aneuploid, indicating a potential etiology for the relatively low implantation efficiency of both natural conceptions and in vitro fertilization (IVF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/1\">",
"       1",
"      </a>",
"      ]. Theoretically, avoiding transfer of aneuploid embryos will reduce the risk of pregnancy failure and improve the probability of conceiving a viable pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The primary populations targeted for this approach are women with the highest risk of having aneuploid embryos, such as women over age 35 or who have had multiple IVF failures or recurrent pregnancy loss. However, PGS has also been promoted to support embryo selection in patients with low probability of having aneuploid embryos.",
"     </li>",
"     <li>",
"      Preimplantation genetic diagnosis (PGD) is performed on a blastomere obtained from a preimplantation embryo or a polar body from an oocyte. The goal is to establish a pregnancy that is unaffected by specific genetic characteristics, such as a known heritable genetic mutation or chromosomal abnormality (eg, translocations) carried by one or both biological parents. It is also used to select embryos for transfer that have specific characteristics, such as a particular gender or compatible HLA type. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"       \"Preimplantation genetic diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When preimplantation genetic testing is planned, assisted reproductive technology (ART) must be used for conception even if infertility is not an issue for the couple. ART is expensive, intrusive, and associated with risks, such as ovarian hyperstimulation syndrome, multiple gestations and risks to singleton gestations that occur more often than in natural conceptions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938001\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common technique is blastomere biopsy; however, many clinics are moving towards blastocyst trophectoderm biopsy with microarrays and 23 chromosome analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938009\">",
"    <span class=\"h2\">",
"     Blastomere biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic analysis is usually performed on one or two nucleated cells (blastomeres) removed three days after fertilization. The embryo typically contains six to nine cells at this stage (",
"    <a class=\"graphic graphic_figure graphicRef55217 \" href=\"mobipreview.htm?35/4/35904\">",
"     figure 1",
"    </a>",
"    ). Biopsy of the embryo on the morning of day 3 allows for a single cell to be easily teased apart from its sibling blastomeres. Compaction of the embryo usually occurs slightly later, on days 3 or 4 days of development, and makes the biopsy procedure impossible to perform because the cells are tightly adherent to one another.",
"   </p>",
"   <p>",
"    Removing a single cell gives information about the chromosomal complement only of that particular cell. The chromosomal complement of the rest of the cells in that embryo must be inferred from the results of the cell that was analyzed. This assumption can lead to erroneous results due to the high prevalence of mosaicism caused by mitotic non-disjunction after the first cell division. Removing a second blastomere might provide clues about the incidence of mosaicism, however, determining whether the second blastomere is normal does not appear to increase the diagnostic performance of the testing method. If the results of testing on each blastomere are discordant (one blastomere normal and the other abnormal), which result should be believed? Additionally, testing more than one cell in the embryo at this stage significantly inhibits the developmental potential of the embryo, thus defeating the purpose of testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/3\">",
"     3",
"    </a>",
"    ]. Therefore, removing a single blastomere for aneuploidy screening on a day 3 embryo is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938016\">",
"    <span class=\"h2\">",
"     Blastocyst biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryos usually reach the blastocyst stage of development five to six days following fertilization (",
"    <a class=\"graphic graphic_figure graphicRef55217 \" href=\"mobipreview.htm?35/4/35904\">",
"     figure 1",
"    </a>",
"    ). Biopsy of trophectoderm cells overlying the anembryonic pole provides up to three dozen cells for analysis. Having more DNA available for analysis reduces the possibility of diagnostic errors. In addition, this technique is the least disruptive to the ART process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/4\">",
"     4",
"    </a>",
"    ]. Unfortunately, laboratory conditions and current culture media are not able to efficiently develop embryos to the blastocyst stage and a significant embryo loss rate occurs between the 8 cell and blastocyst stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Additionally, embryos developed to the blastocyst stage in culture and then transferred appear to have an increased risk of monozygotic twinning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565950972\">",
"    <span class=\"h2\">",
"     Polar body biopsy (PBB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of embryo aneuploidy appears to arise from errors in meiosis. Genetic analysis can be performed on the oocyte by removing the first and, sometimes, the second polar body (",
"    <a class=\"graphic graphic_figure graphicRef53222 \" href=\"mobipreview.htm?26/61/27606\">",
"     figure 2",
"    </a>",
"    ). Since approximately 70 percent of meiotic errors occur during the first meiotic division and prior to fertilization, analysis of this cell (the first polar body) allows the genetic composition of the oocyte to be inferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/8\">",
"     8",
"    </a>",
"    ]. However, disadvantages of this approach are that fertilization of oocytes must be performed before the results of testing are available since the mature oocyte must be fertilized within 12 hours of egg retrieval. Additionally, since only about 70 percent of mature oocytes undergo normal fertilization (two pronuclei), many oocytes will be tested that will either not fertilize or not undergo subsequent development.",
"   </p>",
"   <p>",
"    Post-mitotic errors cannot be detected using this technology without further genetic testing of the embryos.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938023\">",
"    <span class=\"h1\">",
"     GENETIC TESTING METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5939104\">",
"    <span class=\"h2\">",
"     Fluorescence in situ hybridization (FISH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorescence in situ hybridization (FISH) is a method of testing single cells for aneuploidy. &nbsp;There is no standard panel; the specific chromosomes chosen for evaluation depend on the patient&rsquo;s prior history and include those involved in the most common aneuploidies identified in spontaneous miscarriages. Because only a limited number of chromosome pairs from each nucleus can be evaluated by FISH, usually fewer than half, this technique is not commonly used.",
"   </p>",
"   <p>",
"    The technique involves hybridizing fluorescent tagged probes utilizing DNA sequences specific for&nbsp;an individual chromosome to the nucleus from a cell that has been fixed onto a microscope slide. When cooled, the fluorescently labelled probe will anneal to the homologous segments of DNA in the fixed nucleus if present in excess.&nbsp;Non-hybridized probe is washed from the slide and the nucleus is then analyzed under a fluorescent microscope utilizing different wavelengths of light. A normal blastomere should contain two copies (two fluorescent signals) for each chromosome tested. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538631#H15538631\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Fluorescence in situ hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938031\">",
"    <span class=\"h2\">",
"     Comparative genomic hybridization (CGH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparative genomic hybridization (CGH) enables analysis of all 23 chromosome pairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/9\">",
"     9",
"    </a>",
"    ]. Because metaphase CGH is time consuming, results are usually not available before the embryo must be transferred. Therefore, embryos are usually cryopreserved following the biopsy. Those that test normal can be used in future cycles. However, cryopreservation is not ideal, as not all embryos will survive the freezing and thawing process and the developmental potential of surviving embryos may be reduced.",
"   </p>",
"   <p>",
"    Use of micro-array chips for CGH (ie, array CGH) has several advantages over metaphase CGH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. These include the ability to analyze only embryos that have survived to the blastocyst stage and are therefore more likely to be chromosomally normal, the availability of multiple cells for testing, and rapid turnaround time (usually within a few hours) so that embryos can be transferred without the need for cryopreservation. Disadvantages are that array-based CGH cannot detect polyploidies, balanced translocations or inversions, changes in DNA sequences (eg, point mutations), or gains and losses in regions of the genome not covered by the array [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7208?source=see_link\">",
"     \"Use of array comparative genomic hybridization (aCGH) in obstetrics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538652#H15538652\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Array comparative genomic hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938038\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF ANEUPLOIDY SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal result from analysis of a single blastomere removed from a day 3 embryo by any method does not necessarily indicate that the embryo will be abnormal, for the reasons described below. Because of the possibility of false positive errors, embryos initially considered abnormal may be re-analyzed at the blastocyst stage and transferred if re-testing yields a normal result. In addition, because of false negative errors, confirmatory testing during pregnancy is strongly recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120199663\">",
"    <span class=\"h2\">",
"     Biological factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When non-disjunction occurs during meiosis, all of the cells in the embryo typically contain the same chromosomal complement. In contrast, mitotic non-disjunction (postfertilization) yields two or more distinct cell lines and results in an embryo that contains cells with different chromosomal complements. Testing a single, randomly selected cell, and using this information to infer the chromosomal complement of the entire embryo can lead to incorrect conclusions. &nbsp;",
"   </p>",
"   <p>",
"    Examining more than one cell does not guarantee a correct conclusion. Although an embryo containing both normal and aneuploid cells may be identified if two or more cells are removed and analyzed, the actual proportion of normal and abnormal cells varies, depending on the point in development when abnormal segregation occurred. The true proportion of normal to abnormal cells cannot be determined unless all of the cells are analyzed, which obviously destroys the embryo.",
"   </p>",
"   <p>",
"    Furthermore, if there are only one or two abnormal cells in an embryo, biopsy may actually &ldquo;correct&rdquo; the abnormality if the abnormal cell(s) is removed from the embryo, leaving behind only normal cells. In addition, the actual proportion of aneuploid cells in an embryo that will lead to abnormal development is unknown. Evidence from multiple studies suggests that up to half of all embryos identified as aneuploid at the cleavage stage and survive to the blastocyst stage will &ldquo;self correct&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Theories to explain this phenomenon include the failure of abnormal cell lines to proliferate, self-correction of the abnormal cell line, and a false positive or incorrect result from the earlier analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120199670\">",
"    <span class=\"h2\">",
"     Technical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate screening of a single cell with FISH requires a high degree of technical proficiency. Approximately 10 percent of cells removed for screening yield no results or results not confirmed by analysis of the remaining cells in embryos not transferred. The likelihood of obtaining no result or an incorrect result with FISH depends on the number of blastomeres and the number of chromosomes analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Even under ideal circumstances, hybridization efficiency of commercial probes is about 95 to 99 percent, although the actual hybridization efficiency on single blastomeres is unknown.",
"   </p>",
"   <p>",
"    Erroneous results may also be obtained during the interpretation of the fluorescent signals when orientation or overlapping of chromosomes can yield split or diffused signals that are misinterpreted. Failure to spread the nucleus well during fixation may also increase the risk of misinterpretation. Re-analyzing the cell for the same chromosome using a different locus or telomeric probes can reduce the rate of this error when signals are absent or ambiguous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/19\">",
"     19",
"    </a>",
"    ]. Errors arising from the technique used for analysis of the cell should be lower with micro-arrays, although no direct comparisons have been performed.",
"   </p>",
"   <p>",
"    The choice of genetic testing method can also make a difference. A study comparing results obtained with FISH and CGH showed that up to 25 percent of embryos presumed to be normal by FISH tested abnormal by CGH because the abnormal chromosome pair(s) was not among those included in the FISH panel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/20\">",
"     20",
"    </a>",
"    ]. However, due to the high percentage of mosaicism identified in cleavage stage embryos, analysis of all 23 chromosomes by CGH might actually increase the percentage of embryos incorrectly diagnosed as abnormal and discarded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938045\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGS should not be performed to select the best embryo for transfer in couples with no known chromosomal or genetic abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/21\">",
"     21",
"    </a>",
"    ]. There is no high quality evidence that PGS improves clinical pregnancy rates in these couples. This is likely due to the biological and technical limitations discussed above (see",
"    <a class=\"local\" href=\"#H5938038\">",
"     'Limitations of aneuploidy screening'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938611\">",
"    <span class=\"h2\">",
"     Advanced maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials have evaluated the utility of aneuploidy screening of preimplantation embryos for improving live birth rates, primarily in women of advanced maternal age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Each of these trials performed FISH analysis of one or two blastomeres removed from day 3 embryos. Although the selection of patients, method of biopsy, number of chromosomes analyzed, and specific chromosome pairs evaluated varied among the studies, they all came to a similar conclusion: PGS did not increase the ongoing pregnancy rate or delivery rate per started cycle. None of the studies demonstrated a significant difference in miscarriage rates between the PGS and control groups.",
"   </p>",
"   <p>",
"    Combining the results of five randomized trials (total of 1357 patients) showed that patients undergoing PGS actually had a significantly lower probability of live birth than the control group (RR 0.73, 95% CI 0.59-0.90). The incidence of an embryo being classified as &ldquo;abnormal&rdquo; based on FISH results was between 62 and 72 in four trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/22-24,26\">",
"     22-24,26",
"    </a>",
"    ]. When 285 of 413 (69 percent) embryos classified by FISH as abnormal were reanalyzed successfully, 24 (8 percent) were normal (false positives) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/22\">",
"     22",
"    </a>",
"    ]. In 38 patients who had no embryo transfer because all of their embryos were classified as abnormal, three (9.1 percent) had one or more normal embryos discarded due to a false positive result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938060\">",
"    <span class=\"h2\">",
"     IVF implantation failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the transfer of multiple morphologically normal embryos, some patients do not achieve pregnancy. These patients lack an identifiable etiology for their infertility; increased rates of embryo aneuploidy have been implicated. Embryos in these couples have a high rate of testing abnormal (approximately50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In the only randomized trial, patients with recurrent implantation failure were assigned to PGS or no PGS and all patients had a blastocyst transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/29\">",
"     29",
"    </a>",
"    ]. This trial found that patients undergoing PGS had similar implantation rates to the control group (21.4 and 25.3 percent, respectively). Additionally, while not statistically significantly different, the clinical pregnancy rate in the PGS group was only 25.0 percent, while it was 40.3 percent in the control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979585\">",
"    <span class=\"h2\">",
"     IVF for embryo selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing IVF, more than one embryo may be transferred to improve implantation rates because the implantation efficiency of human embryos is significantly less than 50 percent and decreases as women get older. Transfer of more than one embryo can improve implantation rates, but also increases the rate of multiple gestation. Two randomized trials evaluated whether PGS improves embryo implantation rates in &ldquo;good prognosis&rdquo; IVF patients and found no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. One trial reported that, compared to the no PGS group, the PGS group had a significantly lower implantation rate (31.7 versus 62.3 percent), clinical pregnancy rate (52.4 versus 72.7 percent), and live birth rate (28.6 versus 68.2 percent); as well as a lower multiple pregnancy rate (9.1 versus 46.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/30\">",
"     30",
"    </a>",
"    ]. The other trial showed identical results (34.6 percent live birth rate per initiated cycle in each arm) during interim analysis and was halted early due to lack of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120201020\">",
"    <span class=\"h2\">",
"     Recurrent pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of conceptions that end in spontaneous miscarriage and are successfully karyotyped demonstrate a chromosomal abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/9,32\">",
"     9,32",
"    </a>",
"    ]. Embryos from women with recurrent pregnancy loss (RPL) show a high incidence of aneuploidy, even those of younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Although couples with RPL often have no difficulty conceiving a pregnancy, IVF with PGS has been proposed to increase the likelihood of transferring only normal embryos, which might increase the implantation rate, lower the spontaneous loss rate, and thus improve pregnancy outcome in couples who have experienced RPL.",
"   </p>",
"   <p>",
"    No randomized trials have been performed, but findings from some observational studies have provided some support of this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/27,35\">",
"     27,35",
"    </a>",
"    ]. In one study, outcomes from RPL patients undergoing PGS were compared to patients undergoing PGD for sex-linked diseases; ongoing pregnancy rates and miscarriage rates were similar for both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/33\">",
"     33",
"    </a>",
"    ]. Another study compared RPL patients undergoing PGS to patients undergoing IVF because of infertility (no PGS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/34\">",
"     34",
"    </a>",
"    ]. The ongoing pregnancy rate was similar for both groups. However, these studies do not prove the benefit of PGS in management of RPL since the probability of subsequent successful pregnancy in patients with RPL without intervention is already high, approaching 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with RPL who have proven karyotypically normal miscarriages, IVF with PGS is unlikely to be of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938067\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of clinical outcomes of pregnancies following PGS is limited by the relatively small number and young age of living offspring, but does not demonstrate a significantly increased risk of malformations or developmental abnormalities compared to the general population. Continued surveillance of children born as a result of this technology is needed to determine its safety.",
"   </p>",
"   <p>",
"    A European database of clinical pregnancies after preimplantation genetic diagnosis (PGD) reported malformations in 64 of 1214 infants (5.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/38\">",
"     38",
"    </a>",
"    ]. There was no identifiable pattern of anomalies or increased frequency of any specific type of anomaly. A detailed assessment of 109 live births from 97 pregnancies after polar body biopsy reported that six infants (5.5 percent) had minor or major anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/39\">",
"     39",
"    </a>",
"    ]. Another report of 581 children born subsequent to embryo biopsy observed that 2.1 percent had major malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/40\">",
"     40",
"    </a>",
"    ]. These rates of congenital anomalies are within the expected range for the general population and for patients undergoing",
"    <span class=\"nowrap\">",
"     IVF/ICSI.",
"    </span>",
"   </p>",
"   <p>",
"    The mean birthweight of the singleton infants born after embryo biopsy also appears to be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of 44 infants followed to 6 months of age had developmental delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/39\">",
"     39",
"    </a>",
"    ], which is within the expected population frequency, although the sample size is small. Other small studies of 2 year olds conceived after embryo biopsy revealed similar mental and psychomotor developmental outcomes when compared to children conceived after ICSI or naturally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120201685\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples who are considering PGS must be aware of its limitations, as well as the risk of misdiagnosis. Therefore, counseling by an experienced individual prior to proceeding is extremely important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37623/abstract/2\">",
"     2",
"    </a>",
"    ]. The following points are key elements of the counseling process and informed consent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The embryo biopsy procedure itself may negatively affect the viability of the embryo and lower the probability of pregnancy.",
"     </li>",
"     <li>",
"      False positive results may lead to the discard of potentially normal embryos and thus lower the chances for pregnancy.",
"     </li>",
"     <li>",
"      Depending on the number of available embryos, as well as the quality of the developing embryos, a decision may be made to forgo the biopsy and transfer potentially viable embryos.",
"     </li>",
"     <li>",
"      There may be no transfer if all the embryos test abnormal.",
"     </li>",
"     <li>",
"      The patient must be made aware of the limitations of the testing with regard to possibility of both false positive and false negative results, and that not all chromosomes are being tested for.",
"     </li>",
"     <li>",
"      Confirmatory conventional prenatal testing with chorionic villus sampling (CVS) or amniocentesis is recommended for all pregnancies conceived after PGS to avoid misdiagnosis.",
"     </li>",
"     <li>",
"      Alternative approaches should be discussed, such as conventional prenatal testing.",
"     </li>",
"     <li>",
"      The fate of embryos not transferred either due to lack of viability or an abnormal result should be decided upon prior to undergoing IVF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938074\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preimplantation genetic screening (PGS) is performed on oocytes or cell(s) obtained from a preimplantation embryo. Usually one blastomere is removed from a day 3 (about 8 cell) embryo. The goal is to identify de-novo aneuploidy in embryo(s) of couples known or presumed to be chromosomally normal to allow selection of only those embryos with normal karyotypes for transfer. (See",
"      <a class=\"local\" href=\"#H120198825\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common technique is blastomere biopsy; however, many clinics are moving towards blastocyst trophectoderm biopsy with microarrays and 23 chromosome analysis. (See",
"      <a class=\"local\" href=\"#H5938001\">",
"       'Diagnostic techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluorescence in situ hybridization (FISH) can only detect about half of the chromosome pairs from each nucleus. Newer technologies using micro-arrays cells provide more information. (See",
"      <a class=\"local\" href=\"#H5938023\">",
"       'Genetic testing methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the limitations of testing a single cell from a heterogeneous multi-cell embryo, an abnormal result from analysis of a single blastomere by any method does not necessarily indicate that the embryo will be abnormal. Since there are false positives, embryos initially considered abnormal may be re-analyzed at the blastocyst stage and transferred if subsequent testing is normal. (See",
"      <a class=\"local\" href=\"#H5938038\">",
"       'Limitations of aneuploidy screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PGS decreases the chances of live birth. For women of advanced maternal age or a history of IVF implantation failure, we recommend not undergoing PGS (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5938611\">",
"       'Advanced maternal age'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5938060\">",
"       'IVF implantation failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In couples with recurrent pregnancy loss, PGS is unlikely to benefit those with proven karyotypically normal miscarriages. In patients with karyotypically abnormal miscarriages, PGS may decrease the risk of subsequent miscarriage, although there is no evidence that it will increase the probability of having a child. (See",
"      <a class=\"local\" href=\"#H120201020\">",
"       'Recurrent pregnancy loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Couples with recurrent pregnancy loss considering PGS should receive thorough counseling to ensure that they have a good understanding of the techniques used and the possibility of misdiagnosis. (See",
"      <a class=\"local\" href=\"#H120201685\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/1\">",
"      Gianaroli L, Magli MC, Ferraretti AP, et al. Preimplantation genetic diagnosis increases the implantation rate in human in vitro fertilization by avoiding the transfer of chromosomally abnormal embryos. Fertil Steril 1997; 68:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/2\">",
"      Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Preimplantation genetic testing: a Practice Committee opinion. Fertil Steril 2007; 88:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/3\">",
"      Goossens V, De Rycke M, De Vos A, et al. Diagnostic efficiency, embryonic development and clinical outcome after the biopsy of one or two blastomeres for preimplantation genetic diagnosis. Hum Reprod 2008; 23:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/4\">",
"      Carson SA, Gentry WL, Smith AL, Buster JE. Trophectoderm microbiopsy in murine blastocysts: comparison of four methods. J Assist Reprod Genet 1993; 10:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/5\">",
"      Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. Lancet 2004; 363:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/6\">",
"      Johnson N, Blake D, Farquhar C. Blastocyst or cleavage-stage embryo transfer? Best Pract Res Clin Obstet Gynaecol 2007; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/7\">",
"      Vitthala S, Gelbaya TA, Brison DR, et al. The risk of monozygotic twins after assisted reproductive technology: a systematic review and meta-analysis. Hum Reprod Update 2009; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/8\">",
"      Kuliev A, Cieslak J, Ilkevitch Y, Verlinsky Y. Chromosomal abnormalities in a series of 6,733 human oocytes in preimplantation diagnosis for age-related aneuploidies. Reprod Biomed Online 2003; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/9\">",
"      Wilton L, Williamson R, McBain J, et al. Birth of a healthy infant after preimplantation confirmation of euploidy by comparative genomic hybridization. N Engl J Med 2001; 345:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/10\">",
"      Guti&eacute;rrez-Mateo C, Colls P, S&aacute;nchez-Garc&iacute;a J, et al. Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos. Fertil Steril 2011; 95:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/11\">",
"      Hellani A, Abu-Amero K, Azouri J, El-Akoum S. Successful pregnancies after application of array-comparative genomic hybridization in PGS-aneuploidy screening. Reprod Biomed Online 2008; 17:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/12\">",
"      Harper JC, Harton G. The use of arrays in preimplantation genetic diagnosis and screening. Fertil Steril 2010; 94:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/13\">",
"      Baart EB, Martini E, van den Berg I, et al. Preimplantation genetic screening reveals a high incidence of aneuploidy and mosaicism in embryos from young women undergoing IVF. Hum Reprod 2006; 21:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/14\">",
"      Magli MC, Jones GM, Gras L, et al. Chromosome mosaicism in day 3 aneuploid embryos that develop to morphologically normal blastocysts in vitro. Hum Reprod 2000; 15:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/15\">",
"      Li M, DeUgarte CM, Surrey M, et al. Fluorescence in situ hybridization reanalysis of day-6 human blastocysts diagnosed with aneuploidy on day 3. Fertil Steril 2005; 84:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/16\">",
"      Munn&eacute; S, Velilla E, Colls P, et al. Self-correction of chromosomally abnormal embryos in culture and implications for stem cell production. Fertil Steril 2005; 84:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/17\">",
"      Munn&eacute; S, Fischer J, Warner A, et al. Preimplantation genetic diagnosis significantly reduces pregnancy loss in infertile couples: a multicenter study. Fertil Steril 2006; 85:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/18\">",
"      Ferraretti AP, Magli MC, Kopcow L, Gianaroli L. Prognostic role of preimplantation genetic diagnosis for aneuploidy in assisted reproductive technology outcome. Hum Reprod 2004; 19:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/19\">",
"      Colls P, Escudero T, Cekleniak N, et al. Increased efficiency of preimplantation genetic diagnosis for infertility using \"no result rescue\". Fertil Steril 2007; 88:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/20\">",
"      Wilton L, Voullaire L, Sargeant P, et al. Preimplantation aneuploidy screening using comparative genomic hybridization or fluorescence in situ hybridization of embryos from patients with recurrent implantation failure. Fertil Steril 2003; 80:860.",
"     </a>",
"    </li>",
"    <li>",
"     The Practice Committee of the Society for Assisted Reproductive Technology and the Practice Committee of the American Society of Reproductive Medicine. Preimplantation genetic testing: a practice committee opinion. Fertil Steril 2008; 90:S136.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/22\">",
"      Staessen C, Platteau P, Van Assche E, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. Hum Reprod 2004; 19:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/23\">",
"      Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med 2007; 357:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/24\">",
"      Hardarson T, Hanson C, Lundin K, et al. Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial. Hum Reprod 2008; 23:2806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/25\">",
"      Schoolcraft WB, Katz-Jaffe MG, Stevens J, et al. Preimplantation aneuploidy testing for infertile patients of advanced maternal age: a randomized prospective trial. Fertil Steril 2009; 92:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/26\">",
"      Debrock S, Melotte C, Spiessens C, et al. Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilization in women aged at least 35 years: a prospective randomized trial. Fertil Steril 2010; 93:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/27\">",
"      Gianaroli L, Magli MC, Ferraretti AP, Munn&eacute; S. Preimplantation diagnosis for aneuploidies in patients undergoing in vitro fertilization with a poor prognosis: identification of the categories for which it should be proposed. Fertil Steril 1999; 72:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/28\">",
"      Pehlivan T, Rubio C, Rodrigo L, et al. Impact of preimplantation genetic diagnosis on IVF outcome in implantation failure patients. Reprod Biomed Online 2003; 6:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/29\">",
"      Blockeel C, Schutyser V, De Vos A, et al. Prospectively randomized controlled trial of PGS in IVF/ICSI patients with poor implantation. Reprod Biomed Online 2008; 17:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/30\">",
"      Meyer LR, Klipstein S, Hazlett WD, et al. A prospective randomized controlled trial of preimplantation genetic screening in the \"good prognosis\" patient. Fertil Steril 2009; 91:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/31\">",
"      Staessen C, Verpoest W, Donoso P, et al. Preimplantation genetic screening does not improve delivery rate in women under the age of 36 following single-embryo transfer. Hum Reprod 2008; 23:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/32\">",
"      Eiben B, Bartels I, B&auml;hr-Porsch S, et al. Cytogenetic analysis of 750 spontaneous abortions with the direct-preparation method of chorionic villi and its implications for studying genetic causes of pregnancy wastage. Am J Hum Genet 1990; 47:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/33\">",
"      Rubio C, Sim&oacute;n C, Vidal F, et al. Chromosomal abnormalities and embryo development in recurrent miscarriage couples. Hum Reprod 2003; 18:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/34\">",
"      Kahraman S, Benkhalifa M, Donmez E, et al. The results of aneuploidy screening in 276 couples undergoing assisted reproductive techniques. Prenat Diagn 2004; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/35\">",
"      Munn&eacute; S, Sandalinas M, Escudero T, et al. Improved implantation after preimplantation genetic diagnosis of aneuploidy. Reprod Biomed Online 2003; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/36\">",
"      Ogasawara M, Aoki K, Okada S, Suzumori K. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril 2000; 73:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/37\">",
"      Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/38\">",
"      Harper JC, de Die-Smulders C, Goossens V, et al. ESHRE PGD consortium data collection VII: cycles from January to December 2004 with pregnancy follow-up to October 2005. Hum Reprod 2008; 23:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/39\">",
"      Strom CM, Levin R, Strom S, et al. Neonatal outcome of preimplantation genetic diagnosis by polar body removal: the first 109 infants. Pediatrics 2000; 106:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/40\">",
"      Liebaers I, Desmyttere S, Verpoest W, et al. Report on a consecutive series of 581 children born after blastomere biopsy for preimplantation genetic diagnosis. Hum Reprod 2010; 25:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/41\">",
"      Nekkebroeck J, Bonduelle M, Desmyttere S, et al. Mental and psychomotor development of 2-year-old children born after preimplantation genetic diagnosis/screening. Hum Reprod 2008; 23:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/42\">",
"      Middelburg KJ, van der Heide M, Houtzager B, et al. Mental, psychomotor, neurologic, and behavioral outcomes of 2-year-old children born after preimplantation genetic screening: follow-up of a randomized controlled trial. Fertil Steril 2011; 96:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37623/abstract/43\">",
"      Beukers F, van der Heide M, Middelburg KJ, et al. Morphologic abnormalities in 2-year-old children born after in vitro fertilization/intracytoplasmic sperm injection with preimplantation genetic screening: follow-up of a randomized controlled trial. Fertil Steril 2013; 99:408.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14206 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37623=[""].join("\n");
var outline_f36_47_37623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5938074\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H120198825\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938001\">",
"      DIAGNOSTIC TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938009\">",
"      Blastomere biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938016\">",
"      Blastocyst biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565950972\">",
"      Polar body biopsy (PBB)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938023\">",
"      GENETIC TESTING METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5939104\">",
"      Fluorescence in situ hybridization (FISH)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938031\">",
"      Comparative genomic hybridization (CGH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938038\">",
"      LIMITATIONS OF ANEUPLOIDY SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120199663\">",
"      Biological factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120199670\">",
"      Technical factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938045\">",
"      CLINICAL UTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938611\">",
"      Advanced maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938060\">",
"      IVF implantation failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3979585\">",
"      IVF for embryo selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120201020\">",
"      Recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938067\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H120201685\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5938074\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14206|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/4/35904\" title=\"figure 1\">",
"      Preimplantation development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/61/27606\" title=\"figure 2\">",
"      Principles of polar body biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7208?source=related_link\">",
"      Use of array comparative genomic hybridization (aCGH) in obstetrics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37624="Ragged red fibers";
var content_f36_47_37624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Ragged red fibers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skeletal muscle biopsy from another patient shows ragged red muscle fibers admixed with a population of relatively normal muscle fibers (Gomori trichrome stain). The ragged red fibers represent abnormal accumulations of mitochondria beneath the plasma membrane and between the myofibrils.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37624=[""].join("\n");
var outline_f36_47_37624=null;
var title_f36_47_37625="Clinical presentation and diagnostic evaluation of acute pericarditis";
var content_f36_47_37625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnostic evaluation of acute pericarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37625/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37625/contributors\">",
"     Massimo Imazio, MD, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37625/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37625/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/47/37625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pericardium is a fibroelastic sac made up of visceral and parietal layers separated by a (potential) space, the pericardial cavity. In healthy individuals, the pericardial cavity contains 15 to 50 mL of an ultrafiltrate of plasma. Pericardial diseases are relatively common in clinical practice and may have different presentations either as isolated disease or as a manifestation of a systemic disorder. Although the etiology is varied and complex, the pericardium has a relatively non-specific response to these different causes with inflammation of the pericardial layers and possible increased production of pericardial fluid. Chronic inflammation with fibrosis and calcification can lead to a rigid, usually thickened and calcified pericardium, with possible progression to pericardial constriction.",
"   </p>",
"   <p>",
"    Diseases of the pericardium present clinically in one of four ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute and recurrent pericarditis",
"     </li>",
"     <li>",
"      Pericardial effusion without major hemodynamic compromise",
"     </li>",
"     <li>",
"      Cardiac tamponade",
"     </li>",
"     <li>",
"      Constrictive pericarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute pericarditis refers to inflammation of the pericardial sac. The term myopericarditis, or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation. The clinical presentation and diagnostic evaluation for acute pericarditis will be reviewed here. The etiology of pericarditis, treatment and prognosis of acute pericarditis, and other pericardial disease processes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/44/713?source=see_link\">",
"     \"Treatment of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11177?source=see_link\">",
"     \"Recurrent pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=see_link\">",
"     \"Myopericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis is the most common disorder involving the pericardium. Epidemiologic studies are lacking, and the exact incidence and prevalence of acute pericarditis are unknown. However, acute pericarditis is recorded in about 0.1 percent of hospitalized patients and 5 percent of patients admitted to the Emergency Department for nonacute myocardial infarction chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/2\">",
"     2",
"    </a>",
"    ]. In an observational study from an urban area in Northern Italy the incidence of acute pericarditis was 27.7 cases per 100,000 persons per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute pericarditis is a common disorder in several clinical settings, where it may be the first manifestation of an underlying systemic disease or may represent an isolated process (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"mobipreview.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    ). In developed countries, most cases of acute pericarditis are considered of possible or confirmed viral origin, although the exact etiology of most cases remains undetermined following a traditional diagnostic approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the widespread availability of antiretroviral therapy to treat infection with the human immunodeficiency virus (HIV), pericardial disease was the most frequent cardiovascular manifestation of the acquired immune deficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, in developed countries with access to HIV therapy, patients with HIV infection who develop acute pericarditis have an etiologic spectrum very similar to non-HIV infected patients. On the contrary, HIV infection and tuberculosis persist as major causes of acute pericarditis in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25226?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac involvement in HIV-infected patients\", section on 'Pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis can present in a variety of ways, depending on the underlying etiology. Patients with an infectious etiology may present with signs and symptoms of systemic infection such as fever and leukocytosis. Viral etiologies in particular may be preceded by &ldquo;flu-like&rdquo; respiratory or gastrointestinal symptoms. Patients with a known autoimmune disorder or malignancy may present with signs or symptoms specific to their underlying disorder.",
"   </p>",
"   <p>",
"    The major clinical manifestations of acute pericarditis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest pain &ndash; typically sharp and pleuritic, improved by sitting up and leaning forward",
"     </li>",
"     <li>",
"      Pericardial friction rub &ndash; a superficial scratchy or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG) changes &ndash; new widespread ST elevation or PR depression",
"     </li>",
"     <li>",
"      Pericardial effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with acute pericarditis present with chest pain (&gt;95% of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ]. Chest pain is likely to be present in cases of acute pericarditis caused by infection, but may be minimal or absent in patients with uremic pericarditis or pericarditis associated with a rheumatologic disorder (although in some patients pleuritic chest pain and pericarditis is the initial presentation of systemic lupus erythematosus).",
"   </p>",
"   <p>",
"    Chest pain that results from acute pericarditis is typically fairly sudden in onset and occurs over the anterior chest. Unlike pain from myocardial ischemia, chest pain due to pericarditis is most often sharp and pleuritic in nature, with exacerbation by inspiration or coughing. One of the most distinct features is the tendency for a decrease in intensity when the patient sits up and leans forward [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. This position (seated, leaning forward) tends to reduce pressure on the parietal pericardium, particularly with inspiration, and may also allow for splinting of the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, dull, oppressive pain or radiation of the pain to the shoulders (particularly the trapezius ridges) may occur; in such cases it is difficult to distinguish pericarditis from other causes of chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. The chest pain of pericarditis must always be distinguished from other common",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening causes of chest pain such as myocardial ischemia, pulmonary embolism, aortic dissection, gastroesophageal reflux disease, and musculoskeletal pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pericardial friction rub",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a pericardial friction rub on physical examination is highly specific for acute pericarditis (",
"    <a class=\"graphic graphic_movie graphicRef56608 \" href=\"mobipreview.htm?0/18/291\">",
"     movie 1",
"    </a>",
"    ). Pericardial friction rubs, which occur during the maximal movement of the heart within its pericardial sac, are said to be generated by friction between the two inflamed layers of the pericardium. However, this commonly offered explanation for its mechanism may be an oversimplification as patients with a pericardial effusion may also have an audible friction rub.",
"   </p>",
"   <p>",
"    The classic friction rub consists of three phases, corresponding to movement of the heart during atrial systole (which is not heard in patients with atrial fibrillation), ventricular systole, and in the rapid filling phase of early ventricular diastole. However, some rubs are present only during one (one component) or two phases (two components) of the cardiac cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/12\">",
"     12",
"    </a>",
"    ]. In a review of auscultation and phonocardiography in 100 patients with a pericardial rub, the rub was triphasic in 56 percent of patients in sinus rhythm; overall, biphasic rubs were present in 33 percent and monophasic rubs in 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pericardial rubs have a superficial scratchy or squeaking quality that is best heard with the diaphragm of the stethoscope. They may be localized or widespread, but are usually loudest over the left sternal border [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/12\">",
"     12",
"    </a>",
"    ]. The intensity of the rub frequently increases after application of firm pressure with the diaphragm, during suspended respiration, and with the patient leaning forward or resting on elbows and knees (",
"    <a class=\"graphic graphic_picture graphicRef86234 \" href=\"mobipreview.htm?33/51/34623\">",
"     picture 1",
"    </a>",
"    ). This last maneuver is designed to increase contact between visceral and parietal pericardium, but is seldom used in practice since it is cumbersome for the patient.",
"   </p>",
"   <p>",
"    Friction rubs tend to vary in intensity and can come and go over a period of hours; therefore, the sensitivity for detection of a rub is variable and depends in large part on the frequency of auscultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/10\">",
"     10",
"    </a>",
"    ]. Pericardial rubs may be easier to hear in patients without a pericardial effusion, but this finding is not universal and is not well-documented. In a report of 100 patients with acute pericarditis, a pericardial rub was present in 34 of 40 (85 percent) without an effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/13\">",
"     13",
"    </a>",
"    ]. This prevalence is considerably higher than the 35 percent incidence of friction rubs reported in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suspension of respiration during auscultation permits distinction of a pericardial friction rub from a pleuropericardial or pleural rub. A pleuropericardial rub results from the friction between the inflamed pleura and the parietal pericardium, while a pleural rub is the result of friction between the inflamed visceral and parietal pleura. As such, pleuropericardial and pleural rubs can be heard only during the inspiratory phase of respiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link&amp;anchor=H49#H49\">",
"     \"Auscultation of heart sounds\", section on 'Pericardial friction rub and other adventitious sounds'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297355\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the electrocardiogram (ECG) in patients with acute pericarditis signify",
"    <strong>",
"     inflammation of the epicardium",
"    </strong>",
"    , since the parietal pericardium itself is electrically inert. However, some causes of pericarditis do not result in significant inflammation of the epicardium and, as such, may not alter the ECG. An illustration of this is uremic pericarditis, in which there is prominent fibrin deposition but little or no epicardial inflammation. As a result, the ECG usually shows none of the changes associated with pericarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=see_link\">",
"     \"Pericarditis in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297382\">",
"    <span class=\"h3\">",
"     ECG findings with pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) in acute pericarditis can evolve through as many as four stages of changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. However, pericarditis does not always result in significant ECG changes. One series of 300 consecutive patients with acute pericarditis noted typical ECG evolution in 60 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical progression of ECG changes in patients with acute pericarditis is described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1, seen in the first hours to days, is characterized by diffuse ST elevation (typically concave up) with reciprocal ST depression in leads aVR and V1 (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"mobipreview.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). There is also an atrial current of injury, reflected by elevation of the PR segment in lead aVR and depression of the PR segment in other limb leads and in the left chest leads, primarily V5 and V6. Thus, the PR and ST segments typically change in opposite directions. PR segment deviation, which is highly specific though less sensitive, is frequently overlooked.",
"     </li>",
"     <li>",
"      Stage 2, typically seen in the first week, is characterized by normalization of the ST and PR segments.",
"     </li>",
"     <li>",
"      Stage 3 is characterized by the development of diffuse T wave inversions, generally",
"      <strong>",
"       after",
"      </strong>",
"      the ST segments have become isoelectric. However, this stage is not seen in some patients.",
"     </li>",
"     <li>",
"      Stage 4 is represented by normalization of the ECG or indefinite persistence of T wave inversions (\"chronic\" pericarditis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment can accelerate or alter ECG progression. The duration of the ECG changes in pericarditis also depends upon its cause and the extent of the associated myocardial damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atypical ECG changes are seen in up to 40 percent of patients with acute pericarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ]. For example, localized ST-elevation and T-wave inversion occur before ST-segment normalization in a minority of patients with acute pericarditis without myocardial involvement. These changes can simulate ECG changes seen in patients with an acute coronary syndrome. (See",
"    <a class=\"local\" href=\"#H2301545\">",
"     'Differentiating from acute myocardial infarction'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9317?source=see_link\">",
"     \"ECG tutorial: Myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sustained arrhythmias are uncommon in acute pericarditis, except in the post-thoracotomy setting. This was illustrated in a review of 100 consecutive patients in which only seven arrhythmias were identified; all were atrial and all occurred in patients with underlying heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/16\">",
"     16",
"    </a>",
"    ]. In a separate report comparing patients with myopericarditis and simple acute pericarditis, cardiac arrhythmias were also more commonly present in patients with myopericarditis (odds ratio 17.6, 95% confidence interval 5.7 to 54.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the presence of atrial or ventricular arrhythmias is suggestive of concomitant myocarditis or an unrelated cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2301545\">",
"    <span class=\"h3\">",
"     Differentiating from acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;While both acute pericarditis and acute myocardial infarction can present with chest pain and elevations in cardiac biomarkers, the electrocardiographic changes in acute pericarditis differ from those in acute ST elevation MI (STEMI) in several ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/17\">",
"     17",
"    </a>",
"    ]. These distinctions assume that the pericarditis does not occur during or soon after an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=see_link\">",
"     \"Pericardial complications of myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9317?source=see_link\">",
"     \"ECG tutorial: Myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morphology &ndash; The ST segment elevation in acute pericarditis begins at the J point, which represents the junction between the end of the QRS complex (termination of depolarization) and the beginning of the ST segment (onset of ventricular repolarization). The ST segment elevation rarely exceeds 5 mm, and usually retains its normal concavity (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"mobipreview.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). In some cases of acute pericarditis, the ST segment rises obliquely in a straight line. Although similar patterns can occur with STEMI, the typical finding in a STEMI patient is convex (dome-shaped) ST elevation (a pattern not characteristic of acute pericarditis) that may be more than 5 mm in height (",
"      <a class=\"graphic graphic_waveform graphicRef81914 \" href=\"mobipreview.htm?42/18/43306\">",
"       waveform 2",
"      </a>",
"      ). The basis for these morphologic differences is not known, but is probably related to the greater injury current associated with infarction.",
"     </li>",
"     <li>",
"      Distribution &ndash; ST segment elevations in STEMI are characteristically limited to anatomical groupings of leads that correspond to the localized vascular area of the infarct (anteroseptal and anterior leads V1 to V4; lateral leads I, aVL, V5, V6; inferior leads II, III, aVF) (",
"      <a class=\"graphic graphic_waveform graphicRef81914 \" href=\"mobipreview.htm?42/18/43306\">",
"       waveform 2",
"      </a>",
"      ). The pericardium envelops the heart, therefore the ST changes are more generalized and typically are present in most leads (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"mobipreview.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). In pericarditis, ST segment elevation in the precordial leads is most commonly seen in V5 and V6, and in decreasing frequency from V4 to V1, while in the limb leads, it is often more evident in leads I and II than in leads III, aVF, and aVL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reciprocal changes &ndash; Acute STEMI is often associated with reciprocal ST segment changes, which are not seen with pericarditis except in leads aVR and V1.",
"     </li>",
"     <li>",
"      Concurrent ST and T wave changes &ndash; ST segment elevation and T wave inversions do not generally occur simultaneously in pericarditis, while they commonly coexist in acute STEMI (",
"      <a class=\"graphic graphic_waveform graphicRef81914 \" href=\"mobipreview.htm?42/18/43306\">",
"       waveform 2",
"      </a>",
"      ). Furthermore, the evolution of repolarization abnormalities often takes place more slowly and more asynchronously among affected leads in pericarditis than in STEMI.",
"     </li>",
"     <li>",
"      Hyperacute T waves &ndash; Peaked T waves (&gt;10mm high in precordial leads, &gt;5 mm high in limb leads), also referred to as hyperacute T waves, can be seen in STEMI but are not typical of pericarditis (",
"      <a class=\"graphic graphic_waveform graphicRef60464 graphicRef58149 \" href=\"mobipreview.htm?16/15/16634\">",
"       waveform 3A-B",
"      </a>",
"      ). Rarely, fusion of the ST segment and T wave into a single monophasic wave in pericarditis can mimic the appearance of hyperacute T waves.",
"     </li>",
"     <li>",
"      Q waves &ndash; Pathologic Q waves, which may occur with extensive injury in STEMI, are generally not seen in pericarditis. The abnormal Q waves in MI reflect the loss of positive depolarization voltages because of transmural myocardial necrosis. Pericarditis, on the other hand, generally causes only superficial inflammation. Abnormal Q waves are not seen unless there is concomitant myocarditis or preexisting cardiomyopathy or myocardial infarction.",
"     </li>",
"     <li>",
"      PR segment &ndash; PR elevation in aVR with PR depression in other leads due to a concomitant atrial current of injury is frequently seen in acute pericarditis but rarely seen in acute STEMI.",
"     </li>",
"     <li>",
"      QT prolongation &ndash; Prolongation of the QT interval with regional T wave inversion (in the absence of drug effects or relevant metabolic disorders) favors the diagnosis of myocardial ischemia (or myopericarditis) over pericarditis alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2301589\">",
"    <span class=\"h3\">",
"     Differentiation from early repolarization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early repolarization variant seen on an ECG may be present in as many as 30 percent of young adults and is often confused with acute pericarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/18\">",
"     18",
"    </a>",
"    ]. Early repolarization is characterized by ST elevation of the J point, which represents the junction between the end of the QRS complex (termination of depolarization) and the beginning of the ST segment (onset of ventricular repolarization). As a result, there is elevation of the ST segment itself, which maintains its normal configuration (",
"    <a class=\"graphic graphic_waveform graphicRef83883 \" href=\"mobipreview.htm?30/7/30840\">",
"     waveform 4",
"    </a>",
"    ). In early repolarization, ST elevation is most often present in the anterior and lateral chest leads (V3-V6), although other leads can be involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=see_link&amp;anchor=H2#H2\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Early repolarization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following electrocardiographic features can be helpful in distinguishing acute pericarditis from early repolarization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST elevations occur in both the limb and precordial leads in most cases of acute pericarditis (47 of 48 in one study), whereas about one-half of subjects with early repolarization have no ST deviations in the limb leads [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PR deviation and evolution of the ST and T changes strongly favor pericarditis, as neither is seen in early repolarization.",
"     </li>",
"     <li>",
"      The ratio of ST elevation to T wave amplitude in lead V6, if the ratio exceeds 0.24, acute pericarditis is present (positive and negative predictive values are both 100 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2298690\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is often normal in patients with the clinical syndrome of acute pericarditis unless there is an associated pericardial effusion. While the finding of a pericardial effusion in a patient with known or suspected pericarditis supports the diagnosis, the absence of a pericardial effusion or other echocardiographic abnormalities does not exclude it. In one series of 300 consecutive patients with acute pericarditis, pericardial effusion was present in 180 patients (60 percent). In most cases the effusion was small or moderate in size (79 and 10 percent, respectively) without hemodynamic consequences. Cardiac tamponade was present in only 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27077?source=see_link\">",
"     \"Echocardiographic evaluation of the pericardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2298746\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography is typically normal in patients with acute pericarditis. Although patients with a substantial pericardial effusion may exhibit an enlarged cardiac silhouette with clear lung fields (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57640 \" href=\"mobipreview.htm?10/56/11136\">",
"     image 1",
"    </a>",
"    ), this finding is uncommon in acute pericarditis since at least 200 mL of pericardial fluid must accumulate before the cardiac silhouette enlarges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, acute pericarditis should be considered in the evaluation of a patient with new and otherwise unexplained cardiomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2298771\">",
"    <span class=\"h2\">",
"     Cardiac biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis may be associated with increases in serum biomarkers of myocardial injury such as cardiac troponin I or T. In one series of 118 consecutive cases with idiopathic acute pericarditis an elevated level of cardiac troponin I was detected in 38 patients (32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/21\">",
"     21",
"    </a>",
"    ]. Such patients should be considered to have myopericarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=see_link&amp;anchor=H9#H9\">",
"     \"Myopericarditis\", section on 'Laboratory studies'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2300814\">",
"     'Myopericarditis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2298797\">",
"    <span class=\"h2\">",
"     Signs of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since pericarditis is an inflammatory disease, laboratory signs of inflammation are common in patients with acute pericarditis. These include elevations in the white blood cell count, erythrocyte sedimentation rate, and serum C-reactive protein concentration. While elevation in these markers supports the diagnosis, they are neither sensitive nor specific for acute pericarditis. Additionally, in the hyperacute phase of pericarditis, these markers may remain normal and increased levels may be found only on follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute pericarditis is usually suspected based on a history of characteristic pleuritic chest pain, and confirmed if a pericardial friction rub is present. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly. Additional testing, which typically includes blood work, chest radiography, electrocardiography, and echocardiography, can support the diagnosis but is frequently normal or unrevealing. The electrocardiogram is usually the most helpful test in the evaluation of patients with suspected acute pericarditis. Echocardiography is often normal, but can be an essential part of the evaluation if there is evidence of an associated pericardial effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of cardiac tamponade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2298253\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a patient who presents with suspected acute pericarditis, it is our practice to perform the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial history and physical examination &mdash; This evaluation should consider disorders that are known to involve the pericardium, such as prior malignancy, autoimmune disorders, uremia, recent myocardial infarction, and prior cardiac surgery. The examination should pay particular attention to auscultation for a pericardial friction rub and the signs associated with tamponade. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30392?source=see_link\">",
"       \"Etiology of pericardial disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=see_link\">",
"       \"Pericardial disease associated with malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22456?source=see_link&amp;anchor=H8#H8\">",
"       \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\", section on 'Pericardial disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=see_link\">",
"       \"Pericarditis in renal failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=see_link\">",
"       \"Pericardial complications of myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial testing should include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An electrocardiogram in all cases (See",
"      <a class=\"local\" href=\"#H2297355\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiography in all cases (See",
"      <a class=\"local\" href=\"#H2298746\">",
"       'Chest x-ray'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete blood count, troponin level, erythrocyte sedimentation rate, and serum C-reactive protein level (See",
"      <a class=\"local\" href=\"#H2298771\">",
"       'Cardiac biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood cultures if fever higher than 38&ordm;C (100.4&ordm;F) or signs of sepsis",
"     </li>",
"     <li>",
"      Echocardiography should be performed in all cases, with urgent echocardiography if cardiac tamponade is suspected. Even a small effusion can be helpful in confirming the diagnosis of pericarditis, although the absence of an effusion does not exclude the diagnosis. In addition, echocardiography can be particularly helpful if purulent pericarditis is suspected, if there is concern about myocarditis, or if there is radiographic evidence of cardiomegaly, particularly if this is a new finding. (See",
"      <a class=\"local\" href=\"#H2298690\">",
"       'Echocardiogram'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27077?source=see_link\">",
"       \"Echocardiographic evaluation of the pericardium\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The 2003 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/American",
"      </span>",
"      Society of Echocardiography",
"      <span class=\"nowrap\">",
"       (ACC/AHA/ASE)",
"      </span>",
"      guidelines for the clinical application of echocardiography stated that evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement supported the use of echocardiography for the evaluation of all patients with suspected pericardial disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional testing may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"       Tuberculin skin test",
"      </a>",
"      or an interferon-gamma release assay (eg, QuantiFERON TB assay) if not recently performed. The interferon-gamma release assay is most helpful in immunocompromised or HIV positive patients and in regions where tuberculosis is endemic. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link\">",
"       \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2633?source=see_link\">",
"       \"Tuberculous pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antinuclear antibody titer in selected cases (eg, patients with suspected rheumatologic disorder)",
"     </li>",
"     <li>",
"      HIV serology (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25226?source=see_link&amp;anchor=H4#H4\">",
"       \"Cardiac involvement in HIV-infected patients\", section on 'Pericarditis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We",
"      <strong>",
"       do not",
"      </strong>",
"      routinely obtain viral studies, since the yield is low and management is not altered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pericardiocentesis should be performed for therapeutic purposes in patients with cardiac tamponade. (See",
"      <a class=\"local\" href=\"#H2299924\">",
"       'Pericardiocentesis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/44/713?source=see_link&amp;anchor=H12604886#H12604886\">",
"       \"Treatment of acute pericarditis\", section on 'Interventional therapeutic techniques'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericardiocentesis should be considered for diagnostic purposes in patients suspected of having a malignant or bacterial etiology, or in patients with an effusion refractory to medical therapy. (See",
"      <a class=\"local\" href=\"#H2299924\">",
"       'Pericardiocentesis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2300533\">",
"    <span class=\"h2\">",
"     Clinical diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis refers to inflammation of the pericardial sac. The term myopericarditis, or perimyocarditis, is used for cases of acute pericarditis that also demonstrate features consistent with myocardial inflammation.",
"   </p>",
"   <p>",
"    Because the same viruses that are responsible for acute pericarditis can also cause myocarditis, it is not uncommon to find some degree of myocardial involvement in patients with acute pericarditis. The terms \"myopericarditis\" and \"perimyocarditis\" are sometimes used interchangeably or they can be used to indicate the dominant site of involvement. Cases that involve the myocardium in which pericarditis is predominant are reported as myopericarditis; alternatively, the term perimyocarditis is sometimes used when myocardial involvement is most prominent. However, in clinical practice, myopericarditis is more common and this term is often used in both senses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=see_link\">",
"     \"Myopericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2300881\">",
"    <span class=\"h3\">",
"     Acute pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis is diagnosed by the presence of at least two of the following criteria (",
"    <a class=\"graphic graphic_table graphicRef74376 \" href=\"mobipreview.htm?28/1/28700\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4,10,13,23,24\">",
"     4,10,13,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Typical chest pain (sharp and pleuritic, improved by sitting up and leaning forward)",
"     </li>",
"     <li>",
"      Pericardial friction rub (a superficial scratchy or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border) (",
"      <a class=\"graphic graphic_movie graphicRef56608 \" href=\"mobipreview.htm?0/18/291\">",
"       movie 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suggestive changes on the electrocardiogram (typically widespread ST segment elevation) (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"mobipreview.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New or worsening pericardial effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While echocardiography is often normal, and the absence of a pericardial effusion does not exclude pericarditis, echocardiogram remains an essential part of the evaluation if there is evidence of an associated pericardial effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of cardiac tamponade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2300814\">",
"    <span class=\"h3\">",
"     Myopericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When acute pericarditis is present, myopericarditis has been diagnosed by the detection of one or both of the following in the absence of evidence of another cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevation in serum cardiac biomarkers, such as cardiac troponin I or T (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=see_link&amp;anchor=H9#H9\">",
"       \"Myopericarditis\", section on 'Laboratory studies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New or presumed new focal or global left ventricular systolic dysfunction on imaging studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with myocardial inflammation (ie, myopericarditis) commonly have ST and T changes similar to those in patients with pericarditis alone. However, atypical changes are more frequent in patients with myopericarditis. Additional findings indicative of myopericarditis include arrhythmias (particularly ventricular), new bundle branch block or other intraventricular conduction delay, and the development of pathologic Q waves. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=see_link&amp;anchor=H5#H5\">",
"     \"Myopericarditis\", section on 'Electrocardiogram findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospitalization is generally recommended for diagnosis and monitoring in patients with myocardial involvement. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Determination of risk and need for hospitalization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2299910\">",
"    <span class=\"h1\">",
"     IDENTIFYING THE ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The yield of the standard diagnostic evaluation to determine the etiology of acute pericarditis is relatively low. This was illustrated in three series that included a total of 784 unselected patients who underwent an extensive evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/13,23,29\">",
"     13,23,29",
"    </a>",
"    ]. A specific diagnosis was established in only 130 patients (17 percent) (",
"    <a class=\"graphic graphic_table graphicRef60949 \" href=\"mobipreview.htm?16/19/16700\">",
"     table 3",
"    </a>",
"    ). The most commonly confirmed diagnoses were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neoplasia &ndash; 5 percent",
"     </li>",
"     <li>",
"      Tuberculosis &ndash; 4 percent",
"     </li>",
"     <li>",
"      Autoimmune etiologies &ndash; 5 percent",
"     </li>",
"     <li>",
"      Purulent pericarditis &ndash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In Western countries, unless there is an apparent medical or surgical condition known to be associated with pericarditis, most cases of acute pericarditis in immunocompetent patients are due to viral infection or are idiopathic (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"mobipreview.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60949 \" href=\"mobipreview.htm?16/19/16700\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/5,9,24,29-32\">",
"     5,9,24,29-32",
"    </a>",
"    ]. Acute viral or idiopathic pericarditis typically follows a brief and benign course after empiric treatment with antiinflammatory drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/44/713?source=see_link\">",
"     \"Treatment of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the relatively benign course associated with the common causes of pericarditis, it is not necessary to search for the etiology in all patients with acute pericarditis. Initial efforts should focus upon excluding a significant effusion or tamponade and the identification of patients in whom a more comprehensive evaluation should be performed to exclude causes that require specific therapy (eg, malignancy, tuberculosis or purulent pericarditis) (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"mobipreview.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, among patients at high risk of coronary disease, myocardial ischemia must be ruled out by appropriate studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2299917\">",
"    <span class=\"h2\">",
"     Indications for pericardiocentesis and pericardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in patients with acute pericarditis have reported a low yield for diagnostic pericardiocentesis and pericardial biopsy; however, some authors have advocated for a more extensive use of these techniques for diagnostic purposes. The majority of patients with uncomplicated acute pericarditis do not require invasive pericardial procedures. However, some high-risk patients may require pericardiocentesis for both therapeutic and diagnostic purposes (",
"    <a class=\"graphic graphic_table graphicRef69338 \" href=\"mobipreview.htm?8/53/9051\">",
"     table 4",
"    </a>",
"    ). In addition, while pericardial biopsy is not required to make the diagnosis of acute pericarditis, it may rarely be necessary in an attempt to diagnose a specific etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/44/713?source=see_link&amp;anchor=H12604886#H12604886\">",
"     \"Treatment of acute pericarditis\", section on 'Interventional therapeutic techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2299924\">",
"    <span class=\"h3\">",
"     Pericardiocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a pericardial effusion, pericardiocentesis or surgical drainage can serve both diagnostic and therapeutic purposes. Among patients with acute pericarditis, decisions regarding drainage of the pericardial space are based upon the presence of an associated effusion, its echocardiographic characteristics (eg, size and composition), and clinical significance (eg, causing hemodynamic compromise).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptomatic effusions and evidence of cardiac tamponade should undergo prompt pericardial drainage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a significant pericardial effusion is present, a diagnostic pericardiocentesis is indicated if a specific etiology is highly suspected, and diagnosis cannot be reached by other means. The investigation is especially indicated when a neoplastic or bacterial etiology is suspected because a definite diagnosis can only be made by identification of the etiologic agent in the pericardial fluid. Fluid samples should be sent for cytology, tumor markers, gram stain, bacterial cultures, and, if tuberculosis is suspected, polymerase chain reaction testing for tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link\">",
"       \"Diagnosis and treatment of pericardial effusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=see_link\">",
"       \"Pericardial disease associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericardiocentesis may be considered also for large effusions refractory to medical treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Effusions that are small to moderate in size and do not cause hemodynamic compromise (ie, cardiac tamponade) generally",
"      <strong>",
"       do not",
"      </strong>",
"      require drainage, unless a sample of the effusion is necessary for diagnostic purposes. Moreover, pericardiocentesis performed percutaneously has a significantly higher complication rate if the effusion is not large.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion regarding the performance of pericardiocentesis and the treatment of pericardial effusions is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2299967\">",
"    <span class=\"h3\">",
"     Pericardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial biopsy is generally performed as a part of a therapeutic procedure (surgical drainage) in patients with recurrent pericardial effusions and cardiac tamponade after prior pericardiocentesis (therapeutic biopsy), and as a diagnostic procedure in patients with an illness lasting more than three weeks despite treatment without a definite diagnosis. Technical advances in instrumentation with introduction of pericardioscopy, and in contemporary virology and molecular biology have improved the diagnostic value of",
"    <span class=\"nowrap\">",
"     epicardial/pericardial",
"    </span>",
"    biopsy. The diagnostic yield of pericardial biopsy is typically higher in patients with pericardial effusion with or without pericarditis than in those who present with apparent acute pericarditis without effusion. Polymerase chain reaction techniques may represent a useful adjunct to conventional laboratory studies in the investigation of pericardial samples, allowing the rapid identification of microorganisms otherwise not easily found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Tissue samples should be sent for cytology, tumor markers, gram stain, bacterial cultures, and, if tuberculosis is suspected, polymerase chain reaction testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Pericardial fluid analysis and biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DETERMINATION OF RISK AND NEED FOR HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians admit all new cases of acute pericarditis to the hospital, but this may not be necessary. A patient with uncomplicated acute pericarditis can undergo initial evaluation in a same day hospital facility or clinic, although outpatient follow-up is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/5,9,29,32\">",
"     5,9,29,32",
"    </a>",
"    ]. On the other hand, patients with high-risk features are at increased risk of short-term complications and have a higher likelihood of a specific disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]. Hospital admission is indicated for high-risk patients in order to initiate appropriate therapy and a thorough etiologic evaluation.",
"   </p>",
"   <p>",
"    Features of acute pericarditis associated with a higher risk include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (&gt;38&ordm;C [100.4&ordm;F]) and leukocytosis",
"     </li>",
"     <li>",
"      Evidence suggesting cardiac tamponade",
"     </li>",
"     <li>",
"      A large pericardial effusion (ie, an echo-free space of more than 20 mm)",
"     </li>",
"     <li>",
"      Immunosuppressed state",
"     </li>",
"     <li>",
"      A history of oral anticoagulant therapy",
"     </li>",
"     <li>",
"      Acute trauma",
"     </li>",
"     <li>",
"      Failure to respond within seven days to NSAID therapy",
"     </li>",
"     <li>",
"      Elevated cardiac troponin, which suggests myopericarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one report of 300 consecutive patients with acute pericarditis, 15 percent were deemed high risk at presentation and were hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"     9",
"    </a>",
"    ]. In the remaining 85 percent of patients who were low risk, outpatient",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy was effective in 87 percent, and none of these patients had a serious complication (eg, cardiac tamponade) at a mean follow-up of 38 months.",
"   </p>",
"   <p>",
"    Although use of glucocorticoids should not be considered as a risk factor in a general population of patients with acute pericarditis, they were associated with an increased rate of complications in idiopathic or viral pericarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/29\">",
"     29",
"    </a>",
"    ]. Glucocorticoid therapy given in the index attack may increase the chance of recurrence, probably because of its deleterious effect on viral replication and clearance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11177?source=see_link&amp;anchor=H5#H5\">",
"     \"Recurrent pericarditis\", section on 'Predictors of recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gender may also predict the likelihood of complications. In a series of 453 consecutive cases of acute pericarditis, women were at increased risk of complications (hazard ration 1.65, 95% CI 1.08 to 2.52) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37625/abstract/29\">",
"     29",
"    </a>",
"    ]. A possible explanation of this finding is the higher frequency of autoimmune etiologies (above all connective tissue diseases) in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181914389\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute idiopathic or viral pericarditis have a good long-term prognosis. Cardiac tamponade rarely occurs in patients with acute idiopathic pericarditis and is more common in patients with a specific underlying etiology such as malignancy, tuberculosis, or purulent pericarditis. Constrictive pericarditis may occur in about 1 percent of patients with acute idiopathic pericarditis, and is also more common in patients with a specific etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 15 to 30 percent of patients with idiopathic acute pericarditis who are not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    develop either recurrent or incessant disease. Immune mechanisms appear to be of primary importance in the majority of cases, and the term \"chronic autoreactive\" pericarditis has been used. Risk factors for recurrent pericarditis include lack of response to nonsteroidal antiinflammatory drugs, the need for corticosteroid therapy, and inappropriate pericardiotomy or creation of a pericardial window. The pathogenesis, course, and treatment of recurrent pericarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11177?source=see_link\">",
"     \"Recurrent pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38113?source=see_link\">",
"       \"Patient information: Pericarditis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12604290\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute pericarditis (inflammation of the pericardial sac) is the most common disorder of the pericardium and is seen in about 0.1 percent of hospitalized patients and 5 percent of patients admitted to the Emergency Department for nonacute myocardial infarction chest pain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic cases, most of which are probably viral in etiology, are the most common causes of acute pericarditis. Other etiologies of acute pericarditis include any bacterial infections, malignancy, and autoimmune disorders (",
"      <a class=\"graphic graphic_table graphicRef60949 \" href=\"mobipreview.htm?16/19/16700\">",
"       table 3",
"      </a>",
"      ). The distribution of etiologies varies with geography and type of clinical setting (community hospital versus tertiary referral center). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute pericarditis is usually suspected based on a history of characteristic pleuritic chest pain, especially when a pericardial friction rub is present. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a patient with suspected acute pericarditis includes blood work (assessing for markers of inflammation or myocardial damage), chest radiography, electrocardiography, and echocardiography. The electrocardiogram (ECG) is often the most helpful test in the evaluation of patients with suspected acute pericarditis. Echocardiography is often normal, but can be an essential part of the evaluation if there is evidence of an associated pericardial effusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of cardiac tamponade. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2298253\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute pericarditis is diagnosed by the presence of at least two of the following criteria (",
"      <a class=\"graphic graphic_table graphicRef74376 \" href=\"mobipreview.htm?28/1/28700\">",
"       table 2",
"      </a>",
"      ): (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Typical chest pain (sharp and pleuritic, improved by sitting up and leaning forward). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chest pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardial friction rub (a superficial scratchy or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border) (",
"      <a class=\"graphic graphic_movie graphicRef56608 \" href=\"mobipreview.htm?0/18/291\">",
"       movie 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pericardial friction rub'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suggestive changes on the electrocardiogram (typically widespread ST segment elevation) (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"mobipreview.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2297382\">",
"       'ECG findings with pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New or worsening pericardial effusion. (See",
"      <a class=\"local\" href=\"#H2298690\">",
"       'Echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While echocardiography is often normal and the absence of a pericardial effusion does not exclude pericarditis, echocardiography remains an essential part of the evaluation if there is evidence of an associated pericardial effusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of cardiac tamponade. (See",
"      <a class=\"local\" href=\"#H2298690\">",
"       'Echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the relatively benign course associated with the common causes of pericarditis, it is not necessary to search for the etiology in all patients. Initial efforts should focus upon excluding a significant effusion or tamponade and the identification of patients in whom a more comprehensive evaluation should be performed to exclude causes that require specific therapy (eg, malignancy, tuberculosis or purulent pericarditis). (See",
"      <a class=\"local\" href=\"#H2299910\">",
"       'Identifying the etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient with uncomplicated acute pericarditis can undergo initial evaluation in a same-day hospital facility or clinic, although outpatient follow-up is required. Conversely, patients with high-risk features (ie, high fever, large pericardial effusion, cardiac tamponade, failure to respond to empiric antiinflammatory therapy) are at increased risk of short-term complications and have a higher likelihood of a specific disease. Hospital admission is indicated for high-risk patients in order to initiate appropriate therapy and thorough etiologic evaluation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Determination of risk and need for hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/1\">",
"      Imazio M. Contemporary management of pericardial diseases. Curr Opin Cardiol 2012; 27:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/2\">",
"      Spodick DH. Acute cardiac tamponade. N Engl J Med 2003; 349:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/3\">",
"      Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008; 94:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/4\">",
"      Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/5\">",
"      Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med 2004; 351:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/6\">",
"      Little WC, Freeman GL. Pericardial disease. Circulation 2006; 113:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/7\">",
"      Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995; 92:3229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/8\">",
"      Chen Y, Brennessel D, Walters J, et al. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999; 137:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/9\">",
"      Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004; 43:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/10\">",
"      Spodick DH. Acute pericarditis: current concepts and practice. JAMA 2003; 289:1150.",
"     </a>",
"    </li>",
"    <li>",
"     Spodick, DH. Acute, clinically noneffusive (\"dry\") pericarditis. In: Spodick DH: The Pericardium: A Comprehensive Textbook, Marcel Dekker, New York 1997. p.94-113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/12\">",
"      Spodick DH. Pericardial rub. Prospective, Multiple observer investigation of pericardial friction in 100 patients. Am J Cardiol 1975; 35:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/13\">",
"      Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/14\">",
"      Rutsky EA, Rostand SG. Pericarditis in end-stage renal disease: Clinical characteristics and management. Semin Dial 1989; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     Chou TC. Electrocardiography in clinical practice, WB Saunders Company, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/16\">",
"      Spodick DH. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA 1976; 235:39.",
"     </a>",
"    </li>",
"    <li>",
"     Chou TC. Electrocardiography in Clinical Practice: Adults and Pediatrics, 4th ed, WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/18\">",
"      Klatsky AL, Oehm R, Cooper RA, et al. The early repolarization normal variant electrocardiogram: correlates and consequences. Am J Med 2003; 115:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/19\">",
"      Spodick DH. Differential characteristics of the electrocardiogram in early repolarization and acute pericarditis. N Engl J Med 1976; 295:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/20\">",
"      Ginzton LE, Laks MM. The differential diagnosis of acute pericarditis from the normal variant: new electrocardiographic criteria. Circulation 1982; 65:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/21\">",
"      Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. J Am Coll Cardiol 2003; 42:2144.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/23\">",
"      Permanyer-Miralda G, Sagrist&aacute;-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/24\">",
"      Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/25\">",
"      Imazio M and Trinchero R. Myopericarditis: Etiology, management, and prognosis. Int J Cardiol 2008; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/26\">",
"      Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/27\">",
"      Cassimatis DC, Atwood JE, Engler RM, et al. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/28\">",
"      Imazio M, Trinchero R. Triage and management of acute pericarditis. Int J Cardiol 2007; 118:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/29\">",
"      Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/30\">",
"      Maisch B, Risti AD. The classification of pericardial disease in the age of modern medicine. Curr Cardiol Rep 2002; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/31\">",
"      Permanyer-Miralda G. Acute pericardial disease: approach to the aetiologic diagnosis. Heart 2004; 90:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/32\">",
"      Imazio M, Trinchero R. Clinical management of acute pericardial disease: a review of results and outcomes. Ital Heart J 2004; 5:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/33\">",
"      Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37625/abstract/34\">",
"      Imazio M, Brucato A, Derosa FG, et al. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown) 2009; 10:217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4940 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37625=[""].join("\n");
var outline_f36_47_37625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12604290\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pericardial friction rub",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2297355\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2297382\">",
"      - ECG findings with pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2301545\">",
"      - Differentiating from acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2301589\">",
"      - Differentiation from early repolarization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2298690\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2298746\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2298771\">",
"      Cardiac biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2298797\">",
"      Signs of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2298253\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2300533\">",
"      Clinical diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2300881\">",
"      - Acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2300814\">",
"      - Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2299910\">",
"      IDENTIFYING THE ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2299917\">",
"      Indications for pericardiocentesis and pericardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2299924\">",
"      - Pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2299967\">",
"      - Pericardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DETERMINATION OF RISK AND NEED FOR HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181914389\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12604290\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4940|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/56/11136\" title=\"diagnostic image 1\">",
"      Chest x-ray of a pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4940|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/51/34623\" title=\"picture 1\">",
"      Cardiac auscultation supine and leaning forward",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4940|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?0/18/291\" title=\"movie 1\">",
"      Pericardial friction rub",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/0/7181\" title=\"table 1\">",
"      Causes of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/1/28700\" title=\"table 2\">",
"      Diagnosis criteria pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/19/16700\" title=\"table 3\">",
"      Acute pericarditis etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/53/9051\" title=\"table 4\">",
"      Indications for invasive workup in acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4940|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/53/43866\" title=\"waveform 1\">",
"      ECG in pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/18/43306\" title=\"waveform 2\">",
"      ECG in evolving anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/53/42836\" title=\"waveform 3A\">",
"      Hyperacute  or peaked T waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?36/55/37751\" title=\"waveform 3B\">",
"      ECG of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?30/7/30840\" title=\"waveform 4\">",
"      Early repolarization 12 lead ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25226?source=related_link\">",
"      Cardiac involvement in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9317?source=related_link\">",
"      ECG tutorial: Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27077?source=related_link\">",
"      Echocardiographic evaluation of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=related_link\">",
"      Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38113?source=related_link\">",
"      Patient information: Pericarditis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=related_link\">",
"      Pericarditis in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/44/713?source=related_link\">",
"      Treatment of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37626="Treatment and prognosis of Waldenstrm macroglobulinemia";
var content_f36_47_37626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37626/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37626/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37626/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/47/37626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/47/37626/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/47/37626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H54286892\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;macroglobulinemia&rdquo; refers to the production of excess IgM monoclonal protein that occurs in certain clonal lymphoproliferative disorders and plasma cell dyscrasias. This broad definition includes patients with monoclonal gammopathy of undetermined significance of the IgM type (IgM MGUS), smoldering Waldenstr&ouml;m macroglobulinemia (SWM), Waldenstr&ouml;m macroglobulinemia (WM), and a number of related disorders in which an IgM monoclonal protein is detected, such as chronic lymphocytic leukemia (CLL) and a number of lymphoma variants, and primary amyloidosis.",
"   </p>",
"   <p>",
"    WM is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone marrow with an IgM monoclonal gammopathy in the blood. Patients may present with symptoms related to the infiltration of the hematopoietic tissues or the effects of monoclonal IgM in the blood.",
"   </p>",
"   <p>",
"    There is no standard therapy for the treatment of symptomatic WM and no agents have been specifically approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for this disease. Whenever possible, patients should be encouraged to participate in clinical trials. This topic review presents suggestions for the treatment of patients who are not eligible for clinical trials or who choose not to participate in clinical trials.",
"   </p>",
"   <p>",
"    The treatment and prognosis of WM will be reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779381757\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with WM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, serum protein electrophoresis, quantitative immunoglobulins and immunofixation, and beta-2 microglobulin. Serum viscosity should be obtained if the hyperviscosity syndrome is suspected. Hepatitis B serology should be obtained for patients whose planned treatment includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Hepatitis C serology should be considered for patients with cryoglobulinemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link&amp;anchor=H3#H3\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Essential mixed cryoglobulinemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is recommended for all patients.",
"     </li>",
"     <li>",
"      A computed tomography (CT) scan of the chest, abdomen and pelvis should be considered. This study may provide information on the measurement of disease prior to treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with peripheral neuropathy should undergo electromyography (EMG) and evaluation for amyloid deposition. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Neuropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-quarter of patients with WM have no constitutional symptoms or anemia, and no symptoms attributable to their IgM monoclonal protein or tumor infiltration at the time of presentation. These patients are considered to have smoldering (asymptomatic, indolent) WM, and should not be treated until symptoms develop. The decision to postpone treatment in this population is largely based upon their good prognosis without therapy and concerns over the short and long-term complications of treatment.",
"   </p>",
"   <p>",
"    Observational studies that have evaluated a watch-and-wait approach in asymptomatic patients have used varying definitions for what constitutes smoldering WM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/1\">",
"     1",
"    </a>",
"    ]. Anemia and thrombocytopenia have been incorporated as indicators for treatment largely based upon prognostic studies in patients with symptomatic WM. Hemoglobin values that have been used to implement treatment have ranged from &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    to &lt;12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Despite variation in definitions, these studies have all noted that smoldering WM may remain stable without treatment for long periods of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Overall survival approximates that of the normal population with a 10-year survival rate of 70 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of progression to symptomatic disease appears to be highest in the first five years after diagnosis with an estimated annual rate of progression in case series ranging from 4 to 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ]. As an example, a study of 48 patients with smoldering WM followed for a median of 15.4 years (range 0.4 to 24.6 years) reported a cumulative rate of evolution to symptomatic WM, amyloidosis, or lymphoma of 6 percent at one year, 39 percent at three years, 59 percent at five years, and 68 percent at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/8\">",
"     8",
"    </a>",
"    ]. On multivariate analysis, higher serum levels of IgM, lower levels of hemoglobin, and a higher percentage of lymphoplasmacytic cells in the bone marrow were associated with a significantly higher risk of evolution.",
"   </p>",
"   <p>",
"    WM is incurable with current therapy and there is no evidence that the treatment of asymptomatic patients provides a survival benefit when compared with treatment at the time symptoms develop. Treatment is also associated with both short- and long-term complications that can decrease quality of life and potentially affect survival. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    administration can result in a clinically important temporary increase in serum IgM levels (IgM flare), prolonged immunosuppression, and the reactivation of a latent hepatitis B virus infection. As another example, a small percentage of patients treated with nucleoside analogs or alkylating agents develop a more aggressive lymphoma or leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H865115670\">",
"     'Chemotherapy alone'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients who are asymptomatic and have adequate hemoglobin and platelet levels, we recommend observation alone. While the severity of anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia that merits treatment is unknown, we generally consider a hemoglobin &ge;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and platelet count",
"    <span class=\"nowrap\">",
"     &ge;120,000/microL",
"    </span>",
"    to be adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7\">",
"     7",
"    </a>",
"    ]. Asymptomatic patients are followed every four to six months with complete blood counts and monoclonal protein levels. Those who develop symptomatic disease, anemia, or thrombocytopenia are offered therapy. If disease progression is unclear, observation for another three to six months can help to clarify the disease tempo and whether treatment is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is indicated for patients with symptomatic WM. Symptoms can be divided into three major clinical groups: symptoms related to the underlying lymphoproliferative process (eg, constitutional symptoms, cytopenias, or tissue infiltration), hyperviscosity related to the overproduction of IgM, and paraneoplastic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of any of the following symptoms may be used as an indication for the initiation of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic symptoms (weakness, fever, night sweats, fatigue, weight loss, neuropathy), physical findings (lymphadenopathy, hepatomegaly,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenomegaly),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory abnormalities (anemia, thrombocytopenia, neutropenia) require treatment directed against the proliferating malignant cells. These treatment issues will be discussed here.",
"     </li>",
"     <li>",
"      The presence of hyperviscosity is suggested by symptoms and signs such as oronasal bleeding, blurred vision, headaches, dizziness, paresthesias, retinal vein engorgement and flame-shaped hemorrhages, papilledema, and, finally, stupor and coma. It is confirmed by the demonstration of increased serum viscosity, which is usually greater than four centipoise (CP). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Emergent management of hyperviscosity'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link&amp;anchor=H2213249#H2213249\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum viscosity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the paraneoplastic neuropathy is considered separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link&amp;anchor=H5#H5\">",
"       \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Association with plasma cell dyscrasias'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Neuropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;WM cannot be cured with current therapies. Instead, the goals of treatment are to control symptoms and prevent end organ damage. There is no standard therapy for the treatment of WM. However, several prospective trials have demonstrated the efficacy of various drugs to decrease serum IgM levels when given as single agents or in combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7,10-14\">",
"     7,10-14",
"    </a>",
"    ]. In general, it is difficult to compare these agents or regimens based upon response rates alone since individual trials have used different response criteria resulting in widely variable response rates for studies investigating the same regimen. A general approach to the treatment of WM is given in the figures (",
"    <a class=\"graphic graphic_algorithm graphicRef79409 \" href=\"mobipreview.htm?27/3/27710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef58274 \" href=\"mobipreview.htm?29/39/30333\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically, treatment preferences are dependent upon age, the severity of symptoms, eligibility for autologous hematopoietic cell transplantation (HCT), presence of comorbidities, and patient preferences. When choosing a therapy, the following principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy should be reserved for patients with symptomatic disease since asymptomatic patients may do well without therapy and chemotherapy has potential short and long-term complications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are candidates for autologous HCT should avoid treatment with agents that might interfere with stem cell collection (eg, most alkylators, except for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , or nucleoside analogs).",
"     </li>",
"     <li>",
"      The intensity of the regimen is dictated by the severity of symptoms; more intense regimens that may have a quicker response time but increased side effects are offered to patients with highly symptomatic disease while patients with minimal symptoms are offered regimens that are better tolerated, but slower.",
"     </li>",
"     <li>",
"      Patients with symptoms of hyperviscosity require emergent plasmapheresis in addition to therapy directed at the malignant clone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described in the sections below, initial treatment that incorporates",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , (either alone or with other agents), is recommended based upon its low toxicity profile and acceptable response rates. Chemotherapy alone remains an option for patients who are unable to tolerate rituximab therapy. The specific regimen chosen depends upon patient characteristics and tumor burden (",
"    <a class=\"graphic graphic_algorithm graphicRef79409 \" href=\"mobipreview.htm?27/3/27710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef58274 \" href=\"mobipreview.htm?29/39/30333\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Emergent management of hyperviscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperviscosity syndrome is a clinical emergency due to elevated levels of IgM resulting in decreased flow and impaired microcirculation of the central nervous system. Although the diagnosis is established by measuring serum viscosity, the clinician should make the decision to initiate treatment with plasmapheresis on the basis of the patient's symptoms and physical findings (eg, oronasal bleeding, blurred vision, headaches, dizziness, paresthesias, retinal vein engorgement and flame-shaped hemorrhages, papilledema, stupor and coma), rather than on the magnitude of the viscosity measurement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only effective treatment for the hyperviscosity syndrome is the removal of IgM from the circulation via plasmapheresis. The large size of the IgM molecule restricts it mainly to the intravascular space such that it can be rapidly removed with plasmapheresis resulting in prompt alleviation of symptoms. For patients who present with symptoms due to hyperviscosity, or who develop hyperviscosity during treatment, immediate institution of therapeutic plasmapheresis is required. Red blood cell transfusions should be avoided, if possible, prior to plasmapheresis since they might further increase serum viscosity. Once plasmapheresis is complete, patients will need to initiate chemotherapy to control the malignant clone. Details of the plasmapheresis procedure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=see_link\">",
"     \"Plasma exchange in the hyperviscosity syndrome due to immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following general principles regarding plasmapheresis for hyperviscosity syndrome are important:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presenting with severe neurologic impairment, such as stupor or coma in the absence of subdural or intracranial bleeding, should be treated with plasmapheresis",
"      <strong>",
"       emergently",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      Symptoms should subside with the lowering of serum viscosity. However, irreversible changes can occur, such as those due to venous thrombosis in the central nervous system and other sites.",
"     </li>",
"     <li>",
"      Plasmapheresis does not affect the disease process. Thus, cessation of plasmapheresis, in the absence of other therapy, will result in a return to high levels of serum IgM and recurrence of symptoms of hyperviscosity within a few weeks in most instances.",
"     </li>",
"     <li>",
"      A reasonable initial prescription is a total plasma volume exchange (ie, 3 to 4 liters in an adult) replaced with albumin (rather than plasma), repeated daily until symptoms subside or until serum viscosity is normal.",
"     </li>",
"     <li>",
"      Hyperviscosity syndromes are usually associated with an increased plasma volume. Thus, the volume of plasma needed for a \"one volume exchange\" may be greater than that calculated by commonly used formulae.",
"     </li>",
"     <li>",
"      Transfusion with packed red blood cells during this period may further increase whole blood viscosity and precipitate or aggravate heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach is consistent with the 2010 guidelines published by the American Society for Apheresis, which conclude that plasmapheresis is first-line therapy for hyperviscosity syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/15\">",
"     15",
"    </a>",
"    ]. This recommendation is supported by strong evidence from small observational studies demonstrating efficacy of plasmapheresis in this setting and large observational studies demonstrating the safety of plasmapheresis in general. There have been no randomized trials of plasmapheresis in the management of hyperviscosity syndrome. The published literature consists of prospective trials with historical controls, case series, and case reports accumulating data on approximately 300 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/15\">",
"     15",
"    </a>",
"    ]. These studies have demonstrated that a single plasmapheresis treatment reduces IgM levels by 30 to 50 percent and is associated with a decrease in serum viscosity, an increase in capillary blood flow, and improvement in the clinical manifestations of hyperviscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of four patients with hyperviscosity syndrome who underwent 22 plasmapheresis treatments at a single institution evaluated the impact of plasmapheresis on measures of blood viscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/16\">",
"       16",
"      </a>",
"      ]. When compared with findings from an evaluation immediately prior to plasmapheresis, the following outcomes were noted immediately after plasmapheresis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A lower serum IgM concentration (average decrease by 35 percent)",
"     </li>",
"     <li>",
"      A lower average plasma viscosity (2.1 versus 5.0 cp)",
"     </li>",
"     <li>",
"      An increase in spontaneous capillary blood cell flow velocity in finger nailfold capillaries by video microscopy (0.33 versus 0.55",
"      <span class=\"nowrap\">",
"       mm/sec)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another study of nine patients with hyperviscosity syndrome, plasmapheresis resulted in an average decrease in serum IgM and serum viscosity of approximately 45 percent each [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/18\">",
"       18",
"      </a>",
"      ]. Plasmapheresis was also associated with improvements in hyperviscosity-related retinal changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other studies have demonstrated that plasmapheresis is safe and effective for the short-term control of symptoms due to IgM-related hyperviscosity. Complications due to plasmapheresis are seen in less than 2 percent of patients replaced with albumin and most commonly consist of citrate-induced paresthesias, muscle cramps, and urticaria. The complications of plasmapheresis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rituximab-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts agree that first line therapy for most patients with WM should incorporate the monoclonal anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7,14,20\">",
"     7,14,20",
"    </a>",
"    ]. This is largely based upon a low toxicity profile and acceptable response rates in phase II studies. Additionally, a single randomized trial of combination chemotherapy with or without rituximab reported significantly higher response rates and longer event-free survival in patients receiving rituximab-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective, randomized trial investigated the use of CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in 69 previously untreated patients with lymphoplasmacytic lymphoma, 48 of whom met the criteria for WM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients who received rituximab plus CHOP had significantly higher rates of overall response (94 versus 67 percent) and a longer time to treatment failure (63 versus 22 months) when compared with patients who received CHOP alone. Toxicities were similar in the two treatment groups and consisted of neutropenia (grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    in approximately 70 percent of patients), infections (grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    in approximately 10 percent of patients), alopecia, nausea, and vomiting.",
"   </p>",
"   <p>",
"    For most patients with symptomatic WM, we recommend initial treatment with a regimen that incorporates",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (either alone or with other agents) rather than chemotherapy alone. Chemotherapy alone remains an option for patients who are unable to tolerate rituximab therapy or those who progress on rituximab therapy. A transient, yet clinically important increase in serum IgM levels (IgM flare) and viscosity may occur after the administration of rituximab. Clinical and laboratory monitoring is therefore warranted in patients receiving rituximab.",
"   </p>",
"   <p>",
"    General side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include infusion reactions, increased risk of infection, and impaired vaccination responses. Rituximab therapy does impose a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. Side effects of rituximab therapy are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether chemotherapy should be given with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    depends in part upon patient characteristics and tumor burden. In general, we prefer rituximab alone for patients with minimally symptomatic disease, such as those with only modest hematologic compromise (hemoglobin 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or platelets 100,000 to",
"    <span class=\"nowrap\">",
"     120,000/L)",
"    </span>",
"    or immunoglobulin-associated complications (eg, neuropathy or hemolytic anemia). In contrast, we prefer rituximab plus additional chemotherapy for patients with more profound cytopenias (hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or platelets",
"    <span class=\"nowrap\">",
"     &lt;100,000/L),",
"    </span>",
"    bulky disease, constitutional symptoms, or symptoms of hyperviscosity. Patients with symptoms of hyperviscosity should be treated with plasmapheresis prior to initiating rituximab-based therapy directed at the malignant clone. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Emergent management of hyperviscosity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rituximab alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is our preferred treatment option for patients with minimally symptomatic WM. Approximately half of patients will have a partial response to single-agent rituximab; complete responses have not been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Median times to partial and best response are approximately 4 and 17 months, respectively. Side effects are generally well tolerated, but there is frequently a transient increase in serum IgM level (IgM flare) after administration, which can result in symptoms of hyperviscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Emergent management of hyperviscosity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter phase II trial in 69 patients with WM, half of whom were previously untreated, reported objective or minor responses in 52 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, partial response was equally likely in previously untreated (6 of 15) and previously treated (6 of 12) patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/22\">",
"       22",
"      </a>",
"      ]. Patients with a serum monoclonal protein &gt;4.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a serum albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      were least likely to respond to this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two studies, abrupt and clinically important",
"      <strong>",
"       increases",
"      </strong>",
"      in serum IgM levels and viscosity were noted in up to 54 percent of patients at a mean of four weeks (range: one to eight) following initiation of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For symptomatic patients with low tumor burden and for minimally symptomatic patients, we suggest the use of single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    once per week for four weeks rather than other agents. This preference is largely based upon rituximab's low toxicity profile and the desire to avoid the potential damage to stem cells and leukemogenesis associated with alkylating agents and nucleoside analogs in a patient population who do not require a rapid response.",
"   </p>",
"   <p>",
"    Clinical and laboratory monitoring for IgM flare is warranted, especially in those patients with pretreatment IgM levels &gt;5.0",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Typically IgM levels are measured one month after initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy, with the frequency of subsequent measurements based upon response. IgM levels must be rechecked sooner and monitored closely if patients exhibit symptoms of hyperviscosity. Increased levels of IgM may persist for up to four months and do not constitute treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7\">",
"     7",
"    </a>",
"    ]. Delayed responses can occur even in patients who exhibit an initial increase in IgM levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rituximab plus other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy is our preferred treatment option for patients with severe symptoms related to WM (",
"    <a class=\"graphic graphic_algorithm graphicRef79409 \" href=\"mobipreview.htm?27/3/27710\">",
"     algorithm 1",
"    </a>",
"    ). A number of small, prospective trials have demonstrated that high response rates can be more rapidly obtained when rituximab is combined with a second agent, but there are no data on whether the improvement in response rate is accompanied by a significant prolongation of overall survival. Overall response rates range from 59 to 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/20,21,28-32\">",
"     20,21,28-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicities of chemoimmunotherapy reflect those of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and the other agents and usually include myelosuppression and infection. Nucleoside analogs and alkylating agents may result in an increased risk of transformation to aggressive lymphoma or leukemia. They may also impair the collection of stem cells. (See",
"    <a class=\"local\" href=\"#H865115670\">",
"     'Chemotherapy alone'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For symptomatic patients with a high tumor burden (eg, hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    constitutional symptoms, hyperviscosity, or bulky disease), we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy. A choice among regimens is generally made based upon whether the patient is a candidate for high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT). Autologous hematopoietic cell transplantation (HCT) is a treatment option for selected patients with relapsed refractory disease and a good performance status. Patients who are candidates for autologous HCT should avoid treatment with agents that might interfere with stem cell collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865114398\">",
"    <span class=\"h4\">",
"     Regimens not toxic to stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are candidates for autologous HCT should be treated initially with regimens that will not impair the ability to collect stem cells in the future. Several regimens have demonstrated activity in WM and do not appear to be toxic to stem cells. These regimens have not been directly compared with each other in prospective trials. In addition, it is difficult to compare these agents based upon response rates alone since individual trials have used different response criteria. The most commonly used regimens are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (DRC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (BR) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (BRD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/31,33-35\">",
"       31,33-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, a prospective phase II trial of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    -analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was halted due to a high rate of rapid-onset, severe anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/32\">",
"     32",
"    </a>",
"    ]. As such, the combination of lenalidomide plus rituximab is not recommended for the treatment of WM outside of a clinical trial. The following studies have reported on the regimens listed above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial investigated the use of DRC in 72 patients with previously untreated symptomatic WM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/29\">",
"       29",
"      </a>",
"      ]. Overall and complete response rates were 83 and 7 percent, respectively, with two-year overall and progression-free survival rates of 81 and 67 percent, respectively. Median time to response was 4.1 months. Toxicities were generally mild (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      and included nausea, alopecia, and neutropenia. Chills, fever, and headache that occurred during",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      infusion were readily reversible after reduction of the infusion rate.",
"     </li>",
"     <li>",
"      A phase II trial of BRD in 23 patients with symptomatic, previously untreated WM found overall and major response rates of 96 and 83 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/31\">",
"       31",
"      </a>",
"      ]. Median time to minimal response was 1.1 months. Peripheral neuropathy was the most common toxicity with 69 percent of patients developing neuropathy that impaired function. Mandatory prophylactic antiviral therapy was added to the treatment protocol after four of the first seven patients developed herpes zoster. None of the patients who took antiviral prophylaxis developed herpes zoster. Of importance, changes in serum IgM levels may not be reflective of a response in the bone marrow among patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a phase II study, once weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      was combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , which was given weekly during cycles one and four [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/38\">",
"       38",
"      </a>",
"      ]. Among 37 patients treated for relapsed or refractory WM, a minor response or better (ie, 25 percent or greater reduction in monoclonal protein levels) was seen in 81 percent of patients, including two complete responses. The median time to progression was 16 months. Using this weekly schedule of bortezomib, grade 3 neurotoxicity was observed in only two cases (5 percent).",
"     </li>",
"     <li>",
"      A prospective phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 35 patients with symptomatic WM, naive to either agent, reported overall and major response rates of 72 and 64 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/30\">",
"       30",
"      </a>",
"      ]. Neuropathy was the dose limiting toxicity and 11 patients developed neuropathy that impaired function (&ge; grade 2). This neuropathy resolved with cessation of therapy in 10 of these patients at a median of 6.7 months. Dose reductions were required in all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among the available regimens is primarily made based upon the toxicity profiles and the clinician&rsquo;s comfort with the regimen. We prefer DRC to the other two regimens primarily because of its low rate of toxicity and concerns over the higher rate of neuropathy seen with regimens that contain either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    . We administer intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (20 mg on day 1) followed by intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) in addition to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 1 to 5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/29\">",
"     29",
"    </a>",
"    ]. This regimen is repeated every 21 days for a total of six courses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865114406\">",
"    <span class=\"h4\">",
"     Regimens with possible stem cell toxicity and/or risk of transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleoside analogs and alkylating agents have been evaluated for the treatment of patients with WM, but may be associated with stem cell toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a risk of transformation to a higher grade lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/9,39\">",
"     9,39",
"    </a>",
"    ]. The following regimens that incorporate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    appear to be active in WM, but should be avoided, if possible, in patients who are candidates for autologous hematopoietic cell transplantation. Of these regimens, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    plus rituximab based on tolerability, and excellent overall activity in the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; A prospective, multicenter trial evaluated treatment with six cycles of fludarabine (25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for 5 days) plus eight weekly infusions of rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week) in 43 patients with WM who had received less than two prior therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/28\">",
"       28",
"      </a>",
"      ]. The overall response rate was 95 percent (2 percent complete). Median time to best response and time to progression were 19 and 51 months, respectively. Severe toxicities included neutropenia (27 patients), thrombocytopenia (7 patients), and pneumonia (6 patients). After a median follow-up of 40.3 months, there were three patients with transformation to aggressive lymphoma and three cases of",
"      <span class=\"nowrap\">",
"       MDS/AML.",
"      </span>",
"      After three cases of herpes zoster were noted in the first 21 patients, prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      was given to subsequent patients until one year after treatment cessation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; In a prospective, multicenter Italian trial, 43 patients with symptomatic WM were treated with rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) plus fludarabine (25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 2 through 4) and cyclophosphamide (250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 2 through 4), administered every 28 days for up to six cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/40\">",
"       40",
"      </a>",
"      ]. Prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      were mandatory. The overall response rate was 79 percent (12 percent complete) with a median time to 25 and 50 percent reductions in serum monoclonal protein of two and three months, respectively. The median event-free survival was 50 months. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia, which was seen in 88 percent of patients and was prolonged in 44 percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; A phase II trial of four monthly cycles of combination therapy with rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1) plus subcutaneous cladribine (0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      day 1 through 5) in 29 patients with newly diagnosed or previously treated WM reported overall and complete response rates of 90 and 24 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/41\">",
"       41",
"      </a>",
"      ]. The median time to best response was 4 months. The most common toxicities were neutropenia and anemia. These were generally mild with 10 episodes and 1 episode of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia and anemia, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; A phase II trial of bendamustine plus rituximab (BR) in 63 patients with low grade lymphoma included 17 patients with lymphoplasmacytic lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/42\">",
"       42",
"      </a>",
"      ]. Overall and complete response rates were 90 and 60 percent, respectively. The most common toxicity was myelosuppression with severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      leukopenia and thrombocytopenia in 16 and 3 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main toxicities with these regimens are myelosuppression and immunosuppression resulting in infections and a treatment-related mortality rate, which may be as high as 5 percent. In addition, a single-institution retrospective analysis of 439 patients with WM who received nucleoside analog-containing regimens (193 patients), regimens that did not contain nucleoside analogs (136 patients), or observation alone (110 patients) reported a higher combined rate of transformation to an aggressive lymphoma (Richter syndrome), myelodysplasia, or acute leukemia in patients who received nucleoside analog based therapy (6.2 versus 0.4 percent, respectively) after a median follow-up of five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865115670\">",
"    <span class=\"h2\">",
"     Chemotherapy alone",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12860436\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with symptomatic WM, we recommend initial treatment with a regimen that incorporates",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (either alone or with other agents) rather than chemotherapy alone. However, treatment with chemotherapy alone may be an alternative initial therapy in patients with a high tumor burden who are unable to tolerate rituximab therapy. The choice between agents is based on physician and institutional preference.",
"   </p>",
"   <p>",
"    Data to support the choice of agent largely come from a single large, randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , nonrandomized single agent prospective trials of other agents, and retrospective analyses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III trial of 414 patients with previously untreated, symptomatic non-Hodgkin lymphoma, which included 339 patients with WM and 38 patients with lymphoplasmacytic lymphoma, randomly assigned initial therapy with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/43\">",
"       43",
"      </a>",
"      ]. After a median follow-up of 36 months, when compared with chlorambucil, fludarabine resulted in the following outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A trend towards increased overall response rate (49 versus 39 percent), which did not reach statistical significance",
"     </li>",
"     <li>",
"      Superior median progression-free survival (36 versus 27 months)",
"     </li>",
"     <li>",
"      Longer median duration of response (38 versus 20 months)",
"     </li>",
"     <li>",
"      Superior median overall survival (not reached versus 70 months) among patients with WM",
"     </li>",
"     <li>",
"      A higher rate of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (36 versus 18 percent) and a lower cumulative incidence of second malignancy at six years (4 versus 21 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single-institution retrospective analysis of 439 patients with WM who received nucleoside analog-containing regimens (193 patients), regimens that did not contain nucleoside analogs (136 patients), or observation alone (110 patients) reported a higher combined rate of transformation to an aggressive lymphoma (Richter syndrome), myelodysplasia, or acute leukemia in patients who received nucleoside analog based therapy (6.2 versus 0.4 percent, respectively) after a median follow-up of five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main toxicities are myelosuppression and immunosuppression resulting in infections and a treatment-related mortality rate, which may be as high as 5 percent. Nucleoside analogs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    should be avoided in patients who are potential candidates for hematopoietic cell transplantation (HCT). Caution in the use of nucleoside analogs is also advised because of potential stem cell damage and risk of transformation to more aggressive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12860581\">",
"    <span class=\"h3\">",
"     Fludarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, a single large, randomized trial demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    resulted in superior outcomes when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/43\">",
"     43",
"    </a>",
"    ]. Fludarabine has not been directly compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    in a randomized trial. Single agent fludarabine results in overall response rates of approximately 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/5,44-46\">",
"     5,44-46",
"    </a>",
"    ]. The main toxicities are myelosuppression and immunosuppression and treatment related mortality may be as high as 5 percent. As with cladribine, damage to stem cells with the use of this agent may result in impaired stem cell collection or transformation to an aggressive lymphoma or leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/9,39\">",
"     9,39",
"    </a>",
"    ]. Fludarabine can be combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as a first line therapy of patients who are not candidates for hematopoietic cell transplantation. (See",
"    <a class=\"local\" href=\"#H865114406\">",
"     'Regimens with possible stem cell toxicity and/or risk of transformation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 78 patients with low-grade lymphoma (including patients with WM and lymphoplasmacytic lymphoma) treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      reported a complete response rate of 15 percent, median duration of response of 2.5 years, and a 5 percent treatment-related mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large cooperative study treated 182 patients with WM with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day IV for five days, repeated every 28 days for four cycles); four additional cycles were given to responders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/5\">",
"       5",
"      </a>",
"      ]. Complete and partial responses were noted in 2 and 34 percent, respectively; response rates were similar in previously treated and untreated patients. At a median follow-up of 41 months, the estimated rates of five-year overall survival were 62 and 36 percent for previously untreated or previously treated patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    has also demonstrated activity in patients with relapsed or refractory disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      administered to 28 patients with WM resulted in responses in 8 of 26 patients (31 percent) who were resistant to prior therapy and both of the previously untreated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/44\">",
"       44",
"      </a>",
"      ]. Unmaintained remissions lasted for a median of 3.2 years. There were no fatalities associated with this treatment.",
"     </li>",
"     <li>",
"      In another study, 92 patients with WM and primary resistance to, or relapse following, treatment with alkylating agents, were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on days one through five), or a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CAP) every four weeks for six courses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Partial remissions were obtained in 30 and 11 percent of patients receiving fludarabine or CAP, respectively; no complete remissions were seen in either treatment arm. While overall survival rates were similar, responses were more durable in the fludarabine arm (19 versus 3 months), and mucositis and alopecia were less frequent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12860828\">",
"    <span class=\"h3\">",
"     Cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    has been evaluated either alone or as part of a combined regimen in patients with WM. Overall response rates have ranged from 55 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. The main toxicities are myelosuppression and immunosuppression. Damage to stem cells with the use of this agent may result in impaired stem cell collection or transformation to an aggressive lymphoma or leukemia. Cladribine can be combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as a first line therapy of patients who are not candidates for hematopoietic cell transplantation (See",
"    <a class=\"local\" href=\"#H865114406\">",
"     'Regimens with possible stem cell toxicity and/or risk of transformation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 26 patients with previously untreated WM treated with two courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for a seven-day continuous infusion) produced objective responses in 22 patients (85 percent), 3 of which were complete [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/48\">",
"       48",
"      </a>",
"      ]. Treatment was well tolerated, with no acute hematologic toxicity. A marked and sustained reduction of CD4+ lymphocytes occurred in all patients, and may have contributed to an infectious death in one. Five patients relapsed during a median follow-up of 13 months; all five responded to retreatment with cladribine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link\">",
"       \"Overview of infectious complications following purine analog therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A phase II trial evaluated single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      (bolus injection of 0.12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by two-hour IV infusion for five consecutive days at monthly intervals for three courses) in 20 untreated or previously treated patients with WM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/50\">",
"       50",
"      </a>",
"      ]. Complete and partial remissions were noted in 5 and 50 percent, respectively, after a median of three courses of treatment; the overall response rates were similar in previously untreated and treated patients. Survival at a median follow-up of 1.7 years was 85 percent. The major toxicity encountered was myelosuppression, with 60 percent of patients demonstrating grade 3 or 4 neutropenia.",
"     </li>",
"     <li>",
"      Another report evaluated 46 previously treated patients with WM resistant to an alkylating agent and glucocorticoids who were given two seven-day courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by continuous infusion for seven days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/49\">",
"       49",
"      </a>",
"      ]. Response rates were 78, 57, and 22 percent for those relapsing off therapy, with primary resistant disease, or in the later phases of their disease, respectively. Projected median survival was three and 1.1 years in primary refractory disease and refractory relapsed disease, respectively.",
"     </li>",
"     <li>",
"      In a phase II multi-institutional trial, 25 previously treated patients with symptomatic WM received subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/51\">",
"       51",
"      </a>",
"      ]. The overall response rate, including disease stabilization, was 68 percent; the median times to treatment failure and remission duration were less than one year. More experience with this route of treatment is needed before it can be recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chlorambucil",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, a single large, randomized trial demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    resulted in superior outcomes when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/43\">",
"     43",
"    </a>",
"    ]. Chlorambucil has not been directly compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    in a randomized trial. Chlorambucil may be considered for the treatment of older patients (eg, age 70 or older) with a high tumor burden who are unable to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or who have already failed rituximab-based therapy. (See",
"    <a class=\"local\" href=\"#H12860436\">",
"     'Choice of agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    can be administered as a single agent or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and results in response rates of approximately 60 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Side effects of chlorambucil are generally restricted to the occurrence of cytopenias and second cancers. Alkylating agents such as chlorambucil are known to be leukemogenic and acute leukemia or myelodysplastic syndrome has occurred in 8 percent of our patients treated with chlorambucil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/55\">",
"     55",
"    </a>",
"    ]. The estimated cumulative incidence of second malignancy at six years was 21 percent in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, chlorambucil is toxic to stem cells and is therefore not an appropriate therapy for patients who are candidates for autologous hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is initially administered orally at 6 to 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and then adjusted depending upon leukocyte and platelet counts and patient response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/53\">",
"     53",
"    </a>",
"    ]. Alternatively, chlorambucil, with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , may be given on an intermittent schedule at a dose of 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for seven days every four to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/54\">",
"     54",
"    </a>",
"    ]. Therapy should be discontinued after the patient reaches a plateau state characterized by resolution of constitutional symptoms and stabilization of the serum IgM protein concentration. Chlorambucil should be reinstituted at the time of relapse if this occurs &gt;6 months after achieving the plateau state.",
"   </p>",
"   <p>",
"    In a randomized study of 46 patients, objective improvement, as evidenced by either reduction of serum IgM or increase in hemoglobin, occurred in 79 and 68 percent of patients given continuous and intermittent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/54\">",
"     54",
"    </a>",
"    ]. With either schedule, hepatomegaly, splenomegaly, and lymphadenopathy were reduced in 55, 67, and 71 percent of patients, respectively. The median survival was 5.4 years with either regimen, similar to that noted in a nonrandomized study of 167 cases treated with continuous chlorambucil (5.0 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779381971\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated periodically to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Assessing response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Working Group on WM has developed uniform response criteria which are used to measure the effect of treatment for WM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/12,56,57\">",
"     12,56,57",
"    </a>",
"    ]. These criteria should be used to determine the patient's best response to treatment and to define when a relapse has occurred.",
"   </p>",
"   <p>",
"    Patients are evaluated before each treatment cycle to determine how their disease is responding to therapy. This evaluation consists of a history and physical examination in addition to the measurement of monoclonal (M) protein in serum or urine. If the monoclonal protein has disappeared on immunofixation, further evaluation includes a bone marrow aspiration and biopsy and a computed tomography (CT) scan of the abdomen. While initial studies suggest that serum free light chain (sFLC) assays may provide prognostic information, further confirmation is required before sFLC is incorporated into the standard assessment of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Similarly, positron emission tomography (PET) has demonstrated initial prognostic value that requires confirmation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response (CR) &mdash; Disappearance of monoclonal protein by immunofixation; normal serum IgM level; no histological evidence of bone marrow involvement, resolution of any adenopathy, hepatomegaly, or splenomegaly (confirmed by CT scan), and resolution of any signs or symptoms attributable to WM. CR status must be reconfirmed at least six weeks later with a second immunofixation.",
"     </li>",
"     <li>",
"      Very good partial response (VGPR) &mdash; At least 90 percent reduction in serum monoclonal IgM concentration on protein electrophoresis; resolution of any adenopathy, hepatomegaly, or splenomegaly (confirmed by CT scan); and resolution of any signs or symptoms attributable to WM. No new symptoms or signs of active disease. &nbsp;",
"     </li>",
"     <li>",
"      Partial response (PR) &mdash; At least 50 percent but less than 90 percent reduction in serum monoclonal IgM concentration on protein electrophoresis and at least 50 percent decrease in adenopathy, hepatomegaly, and splenomegaly on physical examination or CT scan. No new symptoms or signs of active disease.",
"     </li>",
"     <li>",
"      Minor response (MR) &mdash; At least 25 percent but less than 50 percent reduction of serum monoclonal IgM by protein electrophoresis. No new symptoms or signs of active disease.",
"     </li>",
"     <li>",
"      Stable disease (SD) &mdash; Does not fulfill criteria for MR or progressive disease.",
"     </li>",
"     <li>",
"      Progressive disease (PD) &mdash; Two measurements showing an at least 25 percent increase in serum monoclonal IgM by protein electrophoresis or progression of clinically significant anemia, thrombocytopenia, leukopenia, adenopathy, hepatomegaly, or splenomegaly or increase in symptoms attributable to WM which may include unexplained recurrent fever, drenching night sweats, at least 10 percent body weight loss, hyperviscosity, neuropathy, symptomatic cryoglobulinemia, or amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link\">",
"       \"An overview of amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term \"major response\" is used to identify patients who qualify for a partial, very good partial, or complete response. Serum monoclonal IgM levels provide an easily accessible measure of disease status, but can sometimes fluctuate independent of disease activity. As an example, IgM levels can increase transiently after treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . As such, bone marrow biopsy should be considered in patients with a clinical picture that does not appear concordant with the serum monoclonal IgM level.",
"   </p>",
"   <p>",
"    Importantly, IgM values are dependent upon the method of measurement used (eg, nephelometry, densitometry). As such, sequential response assessments for individual patients should be performed in the same laboratory using the same methodology.",
"   </p>",
"   <p>",
"    Patients who have stable or progressive disease are treated as refractory disease. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment of relapsed or refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779381987\">",
"    <span class=\"h2\">",
"     Role of maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy refers to the prolonged administration of agents with low toxicity profiles in an attempt to prevent progression of disease. Maintenance therapy has been incorporated into the management of other indolent forms of non Hodgkin lymphoma principally based upon its ability to prolong time to progression in these subtypes. There are limited data regarding the use of maintenance therapy in WM and no randomized trials. We reserve the use of maintenance therapy for the research setting until a clinical benefit can be demonstrated and validated for patients with WM.",
"   </p>",
"   <p>",
"    A single-center retrospective analysis of 248 patients with WM who demonstrated an initial response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -containing therapy compared outcomes among those who received (86 patients) maintenance rituximab or did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/61\">",
"     61",
"    </a>",
"    ]. Those who received maintenance rituximab demonstrated longer median progression-free and overall survival times and increased rates of infection. However, there are several limitations to this study that impair general interpretation. Most importantly, maintenance therapy was not randomized. Instead, the use of maintenance therapy was incorporated into the routine care at this center after May 2001. As such, patients who received maintenance rituximab were more likely to have access to novel treatments at the time of progression, potentially affecting overall survival. In addition, patients who received maintenance rituximab were more likely to have attained a complete response and to have demonstrated greater improvements in serum IgM and hematocrit, factors likely to have an impact on progression-free survival.",
"   </p>",
"   <p>",
"    Until further data in support of maintenance therapy are reported, we suggest observation with treatment at the time of progression rather than the use of maintenance therapy. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779381995\">",
"    <span class=\"h2\">",
"     Monitoring for progressive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of a response, patients are seen at periodic intervals to monitor for disease progression. The frequency and extent of these visits depends upon the comfort of both the patient and physician. Our approach to patient surveillance is to schedule patient visits every three months for the first year then every six months. At these visits we perform a history and physical examination, complete blood count, and measurement of monoclonal (M) protein in serum or urine. There is no role for routine imaging studies in the longitudinal follow-up of asymptomatic patients after response assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H858126\">",
"    <span class=\"h2\">",
"     Histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsed or refractory disease must be distinguished from histologic transformation which requires a different treatment approach. Histologic transformation of WM into a rapidly progressive, high-grade malignant lymphoma may occur after a typical low-grade course. The histologic appearance of the transformation has been described as reticulum cell sarcoma, lymphoblastic lymphosarcoma, large-cell lymphoma, or immunoblastic sarcoma. The transformation is usually associated with a decrease in performance status, rapid development of lymphadenopathy, increase in serum lactate dehydrogenase levels, presence of abnormal metaphase cytogenetics of involved bone marrow or lymph nodes, and often a decrease in the serum IgM level. Survival from the time of transformation is usually very short, and response to treatment has been short-lived. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with WM will ultimately relapse after an initial response to therapy. Treatment options for patients with relapsed disease include reinstitution of the initial therapy, use of an alternative first-line agent, or high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT). In general, in patients who have achieved a major response to therapy, it is not necessary to restart therapy based on M protein elevations alone; rather, the criteria for re-initiation of therapy are similar to those used in newly diagnosed patients and include recurrence of symptoms and cytopenias. Palliative splenectomy may be offered to patients with symptomatic, painful splenomegaly or hypersplenism. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Symptomatic patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865114606\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic progressive disease are treated with immunotherapy and chemotherapy to control the malignant clone. There is no standard treatment and have been no randomized trials to guide therapy. The following approach is based upon a review of the existing data, clinical experience and observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For symptomatic patients relapsing more than two years following initial treatment, the first choice is to repeat the original treatment. Patients may respond almost equally well with such an approach as they did the first time.",
"     </li>",
"     <li>",
"      For symptomatic patients relapsing less than two years after initial therapy, we suggest treatment with alternative first-line agents (alone or in combination).",
"     </li>",
"     <li>",
"      Although experience is very limited, selected patients with relapsed WM may be candidates for autologous hematopoietic cell transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of alternative first-line agents in relapsed disease is presented in the sections above, when appropriate. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Initial treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Agents under study include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/62\">",
"     62",
"    </a>",
"    ], perifosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/63\">",
"     63",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/64\">",
"     64",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, panobinostat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/65\">",
"     65",
"    </a>",
"    ], Bcl-2 antisense (oblimersen, Genasense), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    . As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       Everolimus",
"      </a>",
"      (RAD-001) is an inhibitor of the mammalian target of rapamycin. In a phase II study in 50 previously treated patients, a minor response or better was seen in 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/62\">",
"       62",
"      </a>",
"      ]. The estimated progression-free survival rates at 6 and 12 months were 75 and 62 percent, respectively. Additional studies are ongoing. Studies with a related compound",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      (CCI-779) are also planned.",
"     </li>",
"     <li>",
"      Perifosine is an inhibitor of Akt, which is thought to be involved in the signaling pathways involved in the pathogenesis of WM. In a phase II study of 37 patients with relapsed or refractory disease, a minor response or better was seen in 13 patients (35 percent). The median time to progression was 12.6 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The anti-CD52 antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      has been studied in patients with previously treated or previously untreated WM. In a phase II study of alemtuzumab in 28 patients with symptomatic WM (previously untreated or relapsed disease) the overall response rate was 75 percent with one complete response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/64\">",
"       64",
"      </a>",
"      ]. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were leukopenia (57 percent), neutropenia (53 percent), thrombocytopenia (25 percent), infection (18 percent), anemia (11 percent), and rash (11 percent). There were three deaths, one attributed to autoimmune thrombocytopenia and two from infection. A total of four patients developed late-onset autoimmune thrombocytopenia at a median of 13.6 months after therapy.",
"     </li>",
"     <li>",
"      A phase II study evaluated the histone deacetylase inhibitor panobinostat as a single agent in the treatment of 36 patients with symptomatic relapsed or refractory WM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/65\">",
"       65",
"      </a>",
"      ]. No patients achieved a complete or a very good partial response. A partial response and minor response was seen in 22 and 25 percent, respectively. The median progression-free survival was 6.6 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were thrombocytopenia (67 percent), neutropenia (36 percent), anemia (28 percent), leukopenia (22 percent), and fatigue (11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal experience with high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) in WM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. Treatment related mortality appears to be less than 10 percent and autologous HCT may be able to produce long-term responses even in heavily pretreated patients. On the other hand, allogeneic HCT, which carries a much higher risk of non-relapse mortality, should NOT be considered outside the context of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/68,70,71\">",
"     68,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 158 adults with WM who underwent autologous HCT and were reported to the European Bone Marrow Transplant Registry between 1991 and 2005 reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/72\">",
"       72",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rate of nonrelapse mortality at one year was 3.8 percent. A second malignancy developed in 8.4 percent by five years.",
"     </li>",
"     <li>",
"      Rates of progression-free survival, overall survival, and relapse at five years were 40, 66, and 52 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another retrospective review of HCT in 36 patients with WM reported to the Center for International Blood and Marrow Transplant Research between 1986 and 2002, observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/68\">",
"       68",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the 10 patients receiving autologous HCT, three-year non-relapse mortality, relapse rate, progression-free survival, and overall survival were 11, 24, 65, and 70 percent, respectively.",
"     </li>",
"     <li>",
"      The 26 patients who received allogeneic HCT did less well, with the above endpoints being seen in 40, 29, 31, and 46 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another retrospective review included 86 patients with WM who underwent myeloablative (37 patients) or reduced intensity (49 patients) conditioning prior to allogeneic HCT between 1998 and 2005 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/73\">",
"       73",
"      </a>",
"      ]. Fifty-nine patients had chemotherapy sensitive disease at the time of HCT. At a median follow-up of 50 months, the following were observed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who underwent myeloablative conditioning had rates of non-relapse mortality and relapse of 33 and 11 percent at three years, respectively. Progression-free and overall survival rates at five years were 56 and 62 percent, respectively.",
"     </li>",
"     <li>",
"      Patients who underwent reduced intensity conditioning had three-year rates of non-relapse mortality and relapse of 23 and 25 percent. Progression-free and overall survival rates at five years were 49 and 64 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autologous HCT is primarily reserved for selected patients with relapsed disease with a good performance status whose disease is sensitive to chemotherapy at the time of transplantation. Different conditioning regimens have been proposed but none has demonstrated superior efficacy over another. Allogeneic transplantation should be primarily done in the context of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy may be offered as a palliative treatment option for patients with symptomatic, painful splenomegaly and hypersplenism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognostic models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Median survival in WM is approximately five years from the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. However, this is a heterogeneous group and outcomes are variable. A number of multivariate models have been proposed to assess survival in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/53,77-82\">",
"     53,77-82",
"    </a>",
"    ]. Many use similar clinical and laboratory variables in different combinations and it is not clear if any of these models is superior to another. Poor prognostic factors that are common to most of these systems include older age, cytopenias, and an elevated beta-2 microglobulin level (B2M). In addition, initial studies suggest that patients with a high von Willebrand factor antigen level have shorter survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective multicenter observational study created a staging system for WM utilizing serum B2M level, hemoglobin concentration (Hgb), and serum IgM concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage A (low risk) &mdash; B2M &lt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and Hgb &ge;12.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Stage B (medium risk) &mdash; B2M &lt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and Hgb &lt;12.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Stage C (medium risk) &mdash; B2M &ge;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and serum IgM &ge;4.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Stage D (high risk) &mdash; B2M &ge;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and IgM &lt;4.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year rates of overall survival for patients with stage A, B, C, or D disease were 87, 63, 53, and 21 percent, respectively. Rates of five-year progression-free survival were 83, 55, 33, and 12 percent, respectively. Stage D patients had a significantly higher incidence of anemia, hypoalbuminemia, lymphadenopathy, and hepatosplenomegaly than those in other stages.",
"   </p>",
"   <p>",
"    Ten-year follow-up of this cohort has identified elevated serum lactate dehydrogenase (LDH) levels as a poor prognostic factor with value added to both the original model described above and the International Prognostic Staging System for WM (IPSSWM) described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, there appeared to be a subset of patients with \"smoldering macroglobulinemia\" who had an excellent prognosis without treatment. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Asymptomatic patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other studies have noted the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Prognostic Staging System for WM (IPSSWM) formulated with data from a large number of previously untreated, symptomatic patients incorporates five adverse features (age &gt;65, Hgb &le;11.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      platelet count",
"      <span class=\"nowrap\">",
"       &le;100,000/microL,",
"      </span>",
"      beta-2-microglobulin",
"      <span class=\"nowrap\">",
"       &gt;3mg/L,",
"      </span>",
"      and serum IgM &gt;70",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      to stratify patients into low, intermediate, and high risk groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. Low risk patients are those under 65 years of age who have zero or one risk factor. High risk patients are those who have more than two risk factors. Intermediate risk patients are those with two risk factors or those over age 65 who have less than three risk factors. Five-year survival rates for patients in the low, intermediate, and high risk groups were 87, 68, and 36 percent, respectively.",
"     </li>",
"     <li>",
"      In a Swedish population-based study of 1555 patients with WM or lymphoplasmacytic lymphoma diagnosed from 1980 to 2005, relative survival rates (RSR) at five years compared with the general population improved sequentially from 1980-1985 (RSR 0.57; 95% CI 0.46-0.68) to 2001-2005 (RSR 0.78; 95% CI 0.71-0.85) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/76\">",
"       76",
"      </a>",
"      ]. Similarly, an analysis of the United States SEER database that included 2696 patients with WM diagnosed from 1988 to 2005 reported a decline in death rates with each five-year calendar period (hazard ratio [HR] 0.90; 95% CI 0.84-0.96) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/75\">",
"       75",
"      </a>",
"      ]. This improvement in survival appeared to be driven by large improvements in younger patients. The decrease in death rates was greatest in patients &lt;50 years (HR 0.70; 95% CI 0.58-0.84). While the estimated five-year survival for the entire cohort was 52 percent, this varied dramatically by age being 71 percent in patients &lt;70 years and 39 percent in older patients. &nbsp;",
"     </li>",
"     <li>",
"      In a study of 337 symptomatic patients with WM, age &gt;65 and organomegaly were associated with poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/80\">",
"       80",
"      </a>",
"      ]. Patients having neither, one, or both of these adverse factors had 10-year estimated survival rates of 57, 16, and 5 percent, respectively. A beta-2 microglobulin level &ge;4",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      when added to this model, was associated with a threefold increase in the risk of death.",
"     </li>",
"     <li>",
"      Another analysis of 167 patients with WM reported shorter survival in men and patients with absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;1700/microL,",
"      </span>",
"      age &gt;60 years, and hemoglobin (Hgb) concentration &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/53\">",
"       53",
"      </a>",
"      ]. The IgM concentration at diagnosis, signs of hyperviscosity, blood lymphocytosis, percentage of bone marrow lymphoid cells, and organomegaly did not significantly influence survival.",
"     </li>",
"     <li>",
"      In a series of 232 patients with WM, age &ge;65, albumin &lt;4.0",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and the presence of cytopenias were the four factors adversely affecting survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/78\">",
"       78",
"      </a>",
"      ]. Patients with one, two, or three risk factors had five-year survival rates of 87, 62, and 25 percent, respectively.",
"     </li>",
"     <li>",
"      In a prospective study of 72 patients with WM, von Willebrand factor (VWF) antigen levels were &lt;110, 110 to 250, and &gt;250",
"      <span class=\"nowrap\">",
"       units/dL",
"      </span>",
"      in 40, 42, and 18 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/83\">",
"       83",
"      </a>",
"      ]. While low VWF antigen levels were associated with an increased tendency to bleed, levels frequently returned to normal following reduction of the monoclonal IgM levels. In contrast, high VWF antigen levels were associated with worse survival and did not decrease with disease control. The adverse prognosis associated with high VWF antigen levels was independent of the IPSSWM. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with WM have a different microRNA expression pattern when compared with healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/84\">",
"     84",
"    </a>",
"    ]. MicroRNAs are short, noncoding RNAs that downregulate gene expression in many tumor types and also play a role in regulating normal physiologic processes. MicroRNA expression may be involved in the pathogenesis of WM and expression levels may differ among patients of different IPSS risk groups. More studies are required to further evaluate the prognostic potential of microRNAs in WM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865114821\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404116\">",
"    <span class=\"h1\">",
"     WEBSITES FOR ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their patients may search for additional information concerning the treatment of WM on various websites. The following are listed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Cancer Institute provides information for clinicians and patients. Information concerning WM can be found at its website [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The International Waldenstr&ouml;m's Macroglobulinemia Foundation has a website and provides information to patients with WM, friends, family, and members of the medical profession [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Research Fund for Waldenstr&ouml;m's, Ltd. has a website and raises funds for research in WM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/47/37626/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with Waldenstr&ouml;m macroglobulinemia (WM) are asymptomatic (ie, \"smoldering\" WM) and can be observed for months or years after the diagnosis is established before requiring treatment. There is no clear advantage to early therapy (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Asymptomatic patients'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Indications for treatment include (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for treatment'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of systemic symptoms (eg, weakness, fever, night sweats, fatigue, weight loss), along with physical findings (eg, symptomatic lymphadenopathy, hepatomegaly,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenomegaly), and cytopenias (eg, anemia, thrombocytopenia, neutropenia).",
"     </li>",
"     <li>",
"      Signs and symptoms due to the presence of hyperviscosity (eg, oronasal bleeding, blurred vision, headaches, dizziness, paresthesias, retinal vein engorgement and flame-shaped hemorrhages, papilledema, stupor and coma). Patients presenting with severe neurologic impairment, such as stupor or coma, should be treated with plasmapheresis on an EMERGENCY basis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presence of severe neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link&amp;anchor=H5#H5\">",
"       \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Association with plasma cell dyscrasias'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1068435\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are very few comparative data on which to state an absolute opinion concerning the best available treatment for patients with WM. Every effort should be made to enter patients with WM into prospective treatment trials. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Initial treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are asymptomatic and have adequate hemoglobin and platelet levels, we recommend observation alone (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). While the severity of anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia that merits treatment is unknown, we generally consider a hemoglobin &ge;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and platelet count",
"      <span class=\"nowrap\">",
"       &ge;120,000/microL",
"      </span>",
"      to be adequate. Asymptomatic patients are followed every six months with complete blood counts and monoclonal protein levels. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with symptomatic WM, we recommend initial treatment with a regimen that incorporates",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (either alone or with other agents) rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Whether chemotherapy should be given with the rituximab depends in part upon patient characteristics and tumor burden. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Rituximab-based therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For symptomatic patients with low tumor burden and for minimally symptomatic patients, we suggest the use of single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      once per week for four weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Responses may take up to six months to occur and there may be an initial, temporary, but clinically relevant rise in the monoclonal protein level. This treatment can be repeated if the disease relapses in a similar indolent manner. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Rituximab alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic patients with a high tumor burden (eg, hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      constitutional symptoms, hyperviscosity, or bulky disease), we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in combination with other agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of agents depends at least partially upon whether the patient may be a candidate for hematopoietic cell transplantation (HCT). Alkylating agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ) and nucleoside analogs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      ) should NOT be employed in HCT candidates because they may compromise future stem cell collection. We typically use rituximab in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Rituximab plus other agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with symptoms due to hyperviscosity, or who develop hyperviscosity during treatment, we recommend the immediate institution of therapeutic plasmapheresis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Red blood cell transfusions should be avoided, if possible, prior to plasmapheresis since they might further increase serum viscosity. Once plasmapheresis is completed, patients will need to initiate chemotherapy to control the malignant clone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Emergent management of hyperviscosity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Relapsed or refractory disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For symptomatic patients relapsing more than two years following initial treatment, we suggest that the original treatment be repeated first (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic patients relapsing less than two years after initial therapy, we suggest using alternative first-line agents, alone or in combination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although experience is very limited, select patients with chemotherapy sensitive relapsed WM may be candidates for autologous hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/1\">",
"      Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/2\">",
"      Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 2005; 11:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/3\">",
"      Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009; 113:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/4\">",
"      Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23:4662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/5\">",
"      Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstr&ouml;m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/6\">",
"      Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr&ouml;m's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/7\">",
"      Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenstr&ouml;m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/8\">",
"      Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012; 119:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/9\">",
"      Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstr&ouml;m macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/10\">",
"      Johnson SA, Birchall J, Luckie C, et al. Guidelines on the management of Waldenstr&ouml;m macroglobulinaemia. Br J Haematol 2006; 132:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/11\">",
"      Gertz MA. Waldenstr&ouml;m macroglobulinemia: a review of therapy. Am J Hematol 2005; 79:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/12\">",
"      Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107:3442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/13\">",
"      Vijay A, Gertz MA. Waldenstr&ouml;m macroglobulinemia. Blood 2007; 109:5096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/14\">",
"      Fonseca R, Hayman S. Waldenstr&ouml;m macroglobulinaemia. Br J Haematol 2007; 138:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/15\">",
"      Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/16\">",
"      Reinhart WH, Lutolf O, Nydegger UR, et al. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstr&ouml;m and multiple myeloma: influence on blood rheology and the microcirculation. J Lab Clin Med 1992; 119:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/17\">",
"      H&ouml;ffkes HG, Heemann UW, Teschendorf C, et al. Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenstr&ouml;m's type. Clin Nephrol 1995; 43:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/18\">",
"      Menke MN, Feke GT, McMeel JW, Treon SP. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. Invest Ophthalmol Vis Sci 2008; 49:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/19\">",
"      Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012; 119:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/20\">",
"      Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/21\">",
"      Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/22\">",
"      Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstr&ouml;m's macroglobulinemia with rituximab. J Clin Oncol 2002; 20:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/23\">",
"      Treon SP, Agus DB, Link B, et al. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991) 2001; 24:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/24\">",
"      Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004; 45:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/25\">",
"      Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstr&ouml;m macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/26\">",
"      Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/27\">",
"      Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/28\">",
"      Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstr&ouml;m macroglobulinemia. Blood 2009; 113:3673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/29\">",
"      Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstr&ouml;m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25:3344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/30\">",
"      Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/31\">",
"      Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstr&ouml;m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27:3830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/32\">",
"      Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/33\">",
"      Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr&ouml;m Macroglobulinemia. Am J Hematol 2010; 85:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/34\">",
"      Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr&ouml;m macroglobulinaemia. Br J Haematol 2010; 151:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/35\">",
"      Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/36\">",
"      Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13:3320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/37\">",
"      Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/38\">",
"      Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/39\">",
"      Tournilhac O, Cazin B, Lepr&egrave;tre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/40\">",
"      Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/41\">",
"      Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010; 28:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/42\">",
"      Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/43\">",
"      Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr&ouml;m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013; 31:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/44\">",
"      Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstr&ouml;m's macroglobulinemia. Am J Med 1993; 95:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/45\">",
"      Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr&ouml;m's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/46\">",
"      Leblond V, L&eacute;vy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstr&ouml;m macroglobulinemia in first relapse or with primary refractory disease. Blood 2001; 98:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/47\">",
"      Yang K, Tan J, Wu T. Alkylating agents for Waldenstrom's macroglobulinaemia. Cochrane Database Syst Rev 2009; :CD006719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/48\">",
"      Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstr&ouml;m's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/49\">",
"      Dimopoulos MA, Weber D, Delasalle KB, et al. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/50\">",
"      Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenstr&ouml;m macroglobulinaemia. Br J Haematol 1998; 103:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/51\">",
"      Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstr&ouml;m's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 1997; 99:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/52\">",
"      Laurencet FM, Zulian GB, Guetty-Alberto M, et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999; 79:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/53\">",
"      Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstr&ouml;m's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/54\">",
"      Kyle RA, Greipp PR, Gertz MA, et al. Waldenstr&ouml;m's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/55\">",
"      Rosner F, Gr&uuml;nwald HW. Multiple myeloma and Waldenstr&ouml;m's macroglobulinemia terminating in acute leukemia. Review with emphasis on karyotypic and ultrastructural abnormalities. N Y State J Med 1980; 80:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/56\">",
"      Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/57\">",
"      Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstr&ouml;m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013; 160:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/58\">",
"      Itzykson R, Le Garff-Tavernier M, Katsahian S, et al. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica 2008; 93:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/59\">",
"      Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008; 49:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/60\">",
"      Banwait R, O'Regan K, Campigotto F, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol 2011; 86:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/61\">",
"      Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab na&iuml;ve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011; 154:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/62\">",
"      Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/63\">",
"      Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010; 16:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/64\">",
"      Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstr&ouml;m macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011; 118:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/65\">",
"      Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstr&ouml;m macroglobulinemia. Blood 2013; 121:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/66\">",
"      Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstr&ouml;m's macroglobulinaemia. Br J Haematol 1999; 105:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/67\">",
"      Martino R, Shah A, Romero P, et al. Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 23:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/68\">",
"      Anagnostopoulos A, Hari PN, P&eacute;rez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/69\">",
"      Anderson LD, Sandmaier BM, Maris MB, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for refractory Waldenstrom's macroglobulinemia (WM): Evidence for a graft-versus-WM effect (abstract). Blood 2006; 108:862a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/70\">",
"      Garnier A, Robin M, Larosa F, et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstr&ouml;m&rsquo;s macroglobulinemia. Results of a retrospective analysis of the Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Moelle et de Th&eacute;rapie Cellulaire. Haematologica 2010; 95:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/71\">",
"      Kyriakou C, Canals C, Taghipour G, et al. Allogeneic stem cell transplantation in Waldenstrom macroglobulinemia: An analysis of 106 cases from the European Bone Marrow Registry (abstract). Haematologica 2007; 92:WM3.9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/72\">",
"      Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/73\">",
"      Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstr&ouml;m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:4926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/74\">",
"      Humphrey JS, Conley CL. Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature. Am J Hematol 1995; 48:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/75\">",
"      Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstr&ouml;m macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012; 53:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/76\">",
"      Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstr&ouml;m macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 2013; 88:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/77\">",
"      Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstr&ouml;m's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/78\">",
"      Morel P, Monconduit M, Jacomy D, et al. patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/79\">",
"      Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/80\">",
"      Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/81\">",
"      Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113:4163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/82\">",
"      Dimopoulos MA, Kastritis E, Delimpassi S, et al. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 2008; 93:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/83\">",
"      Hivert B, Caron C, Petit S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood 2012; 120:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/47/37626/abstract/84\">",
"      Roccaro AM, Sacco A, Chen C, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstr&ouml;m macroglobulinemia. Blood 2009; 113:4391.",
"     </a>",
"    </li>",
"    <li>",
"     Search under Plasma cell neoplasms at: www.cancer.gov (Accessed on September 21, 2006).",
"    </li>",
"    <li>",
"     www.iwmf.com (Accessed on September 21, 2006).",
"    </li>",
"    <li>",
"     www.waldenstromsresearch.org (Accessed on September 21, 2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6654 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37626=[""].join("\n");
var outline_f36_47_37626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54286892\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H779381757\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Emergent management of hyperviscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rituximab-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rituximab alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rituximab plus other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H865114398\">",
"      Regimens not toxic to stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H865114406\">",
"      Regimens with possible stem cell toxicity and/or risk of transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H865115670\">",
"      Chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12860436\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12860581\">",
"      - Fludarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12860828\">",
"      - Cladribine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chlorambucil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H779381971\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Assessing response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H779381987\">",
"      Role of maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H779381995\">",
"      Monitoring for progressive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H858126\">",
"      Histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF RELAPSED OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H865114606\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognostic models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865114821\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6404116\">",
"      WEBSITES FOR ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1068435\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Relapsed or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6654\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6654|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?27/3/27710\" title=\"algorithm 1\">",
"      Treatment of newly diagnosed WM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?29/39/30333\" title=\"algorithm 2\">",
"      Treatment of relapsed WM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=related_link\">",
"      Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_47_37627="Classification lipodystrophy";
var content_f36_47_37627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of lipodystrophic disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Familial/congenital lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total lipoatrophy (Berardinelli - Seip syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Partial lipoatrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dunningan variety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Koeberling variety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lipodystrophy with other dysmorphic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other varieties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Aquired lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total lipoatrophy (Lawrence syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Partial lipoatrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Upper atrophy-lower hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dermatome pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV protease inhibitor-associated lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Localized lipodystrophies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pressure-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Panniculitis variety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Centrifugal variety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37627=[""].join("\n");
var outline_f36_47_37627=null;
var title_f36_47_37628="Help paying for your medicines PI";
var content_f36_47_37628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Help paying for your medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        These Web sites provide information about different programs to help you pay for your medicines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Benefits Checkup (National Council on Aging):",
"        </strong>",
"        This site gives people lists of services and programs for which they can apply. The lists include programs to help pay for medicines, but also programs that don't have to do with healthcare directly. For example, this site has information on finding housing, getting food stamps, and finding elder care. You can search for all types of programs at once or target your search to find a specific kind of service.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.benefitscheckup.org\" target=\"_blank\">",
"           www.benefitscheckup.org",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-800-677-1116",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Needymeds:",
"        </strong>",
"        This is an independent non-profit organization that provides information about patient assistance from drug companies and the government. The site also offers people a discount card that they can use on prescriptions if they have no insurance or choose not to use their insurance. This card is especially useful in paying for medicines after you reach the Medicare \"donut hole\" and Medicare is no longer paying for your prescriptions.",
"        <ul>",
"         <li>",
"          General site:",
"          <a href=\"file://www.needymeds.org\" target=\"_blank\">",
"           www.needymeds.org",
"          </a>",
"         </li>",
"         <li>",
"          Site with state health insurance assistance program (SHIP) information:",
"          <a href=\"file://www.needymeds.org/indices/ship.shtml\" target=\"_blank\">",
"           file://www.needymeds.org/indices/ship.shtml",
"          </a>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Partnership for Prescription Assistance:",
"        </strong>",
"        This program is run by drug companies and their trade group. It is only for people who do not have prescription drug coverage. The site helps people find programs that will get them medicines for free or for a reduced cost.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.pparx.org\" target=\"_blank\">",
"           www.pparx.org",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-888-4PPA-NOW (1-888-477-2669)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rx Assist:",
"        </strong>",
"        This site lets you enter the name of a medicine or the name of a drug company to find programs that can help you get that medicine or medicines made by that company at a reduced cost. In many cases, the online applications for those programs are included.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://rxassist.org/search/default.cfm\" target=\"_blank\">",
"           file://rxassist.org/search/default.cfm",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-401-729-3284",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rx Outreach:",
"        </strong>",
"        This site offers medicines and diabetic treatment supplies at a reduced cost to people who make less than a certain amount of money each year.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.rxoutreach.org\" target=\"_blank\">",
"           www.rxoutreach.org",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-800-769-3880",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37628=[""].join("\n");
var outline_f36_47_37628=null;
var title_f36_47_37629="Distribution serum CK";
var content_f36_47_37629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of serum CK in different population groups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Sex and ancestry",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       BMI",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Serum CK distribution",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       &gt;ULN (N percent)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       2.5th percentile",
"      </td>",
"      <td class=\"subtitle2\">",
"       Median",
"      </td>",
"      <td class=\"subtitle2\">",
"       97.5th percentile",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       All subjects&bull;",
"      </td>",
"      <td>",
"       1411",
"      </td>",
"      <td>",
"       45 (7)",
"      </td>",
"      <td>",
"       27 (5)",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       111",
"      </td>",
"      <td>",
"       460",
"      </td>",
"      <td>",
"       508 (36)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Women",
"      </td>",
"      <td class=\"sublist_other\">",
"       831",
"      </td>",
"      <td class=\"sublist_other\">",
"       45 (7)",
"      </td>",
"      <td class=\"sublist_other\">",
"       28 (6)",
"      </td>",
"      <td class=\"sublist_other\">",
"       36",
"      </td>",
"      <td class=\"sublist_other\">",
"       95",
"      </td>",
"      <td class=\"sublist_other\">",
"       349",
"      </td>",
"      <td class=\"sublist_other\">",
"       304 (37)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Men",
"      </td>",
"      <td class=\"sublist_other\">",
"       580",
"      </td>",
"      <td class=\"sublist_other\">",
"       46 (7)",
"      </td>",
"      <td class=\"sublist_other\">",
"       26 (4)",
"      </td>",
"      <td class=\"sublist_other\">",
"       51",
"      </td>",
"      <td class=\"sublist_other\">",
"       143",
"      </td>",
"      <td class=\"sublist_other\">",
"       616",
"      </td>",
"      <td class=\"sublist_other\">",
"       204 (35)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       White subjects",
"      </td>",
"      <td>",
"       503",
"      </td>",
"      <td>",
"       48 (7)",
"      </td>",
"      <td>",
"       26 (5)",
"      </td>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       88",
"      </td>",
"      <td>",
"       286",
"      </td>",
"      <td>",
"       64 (13)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Women",
"      </td>",
"      <td class=\"sublist_other\">",
"       252",
"      </td>",
"      <td class=\"sublist_other\">",
"       47 (7)",
"      </td>",
"      <td class=\"sublist_other\">",
"       26 (5)",
"      </td>",
"      <td class=\"sublist_other\">",
"       29",
"      </td>",
"      <td class=\"sublist_other\">",
"       72",
"      </td>",
"      <td class=\"sublist_other\">",
"       201",
"      </td>",
"      <td class=\"sublist_other\">",
"       21 (8)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Men",
"      </td>",
"      <td class=\"sublist_other\">",
"       251",
"      </td>",
"      <td class=\"sublist_other\">",
"       48 (7)",
"      </td>",
"      <td class=\"sublist_other\">",
"       26 (4)",
"      </td>",
"      <td class=\"sublist_other\">",
"       47",
"      </td>",
"      <td class=\"sublist_other\">",
"       110",
"      </td>",
"      <td class=\"sublist_other\">",
"       322",
"      </td>",
"      <td class=\"sublist_other\">",
"       43 (17)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       South Asian subjects",
"      </td>",
"      <td>",
"       270",
"      </td>",
"      <td>",
"       44 (6)",
"      </td>",
"      <td>",
"       27 (5)",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       104",
"      </td>",
"      <td>",
"       382",
"      </td>",
"      <td>",
"       62 (23)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Women",
"      </td>",
"      <td class=\"sublist_other\">",
"       147",
"      </td>",
"      <td class=\"sublist_other\">",
"       45 (6)",
"      </td>",
"      <td class=\"sublist_other\">",
"       27 (5)",
"      </td>",
"      <td class=\"sublist_other\">",
"       37",
"      </td>",
"      <td class=\"sublist_other\">",
"       87",
"      </td>",
"      <td class=\"sublist_other\">",
"       313",
"      </td>",
"      <td class=\"sublist_other\">",
"       23 (16)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Men",
"      </td>",
"      <td class=\"sublist_other\">",
"       123",
"      </td>",
"      <td class=\"sublist_other\">",
"       44 (6)",
"      </td>",
"      <td class=\"sublist_other\">",
"       26 (5)",
"      </td>",
"      <td class=\"sublist_other\">",
"       47",
"      </td>",
"      <td class=\"sublist_other\">",
"       143",
"      </td>",
"      <td class=\"sublist_other\">",
"       641",
"      </td>",
"      <td class=\"sublist_other\">",
"       39 (32)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Black subjects",
"      </td>",
"      <td>",
"       570",
"      </td>",
"      <td>",
"       44 (6)",
"      </td>",
"      <td>",
"       28 (5)",
"      </td>",
"      <td>",
"       51",
"      </td>",
"      <td>",
"       149",
"      </td>",
"      <td>",
"       627",
"      </td>",
"      <td>",
"       278 (49)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Women",
"      </td>",
"      <td class=\"sublist_other\">",
"       387",
"      </td>",
"      <td class=\"sublist_other\">",
"       43 (6)",
"      </td>",
"      <td class=\"sublist_other\">",
"       29 (6)",
"      </td>",
"      <td class=\"sublist_other\">",
"       48",
"      </td>",
"      <td class=\"sublist_other\">",
"       124",
"      </td>",
"      <td class=\"sublist_other\">",
"       414",
"      </td>",
"      <td class=\"sublist_other\">",
"       164 (42)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Men",
"      </td>",
"      <td class=\"sublist_other\">",
"       183",
"      </td>",
"      <td class=\"sublist_other\">",
"       44 (6)",
"      </td>",
"      <td class=\"sublist_other\">",
"       26 (4)",
"      </td>",
"      <td class=\"sublist_other\">",
"       71",
"      </td>",
"      <td class=\"sublist_other\">",
"       213",
"      </td>",
"      <td class=\"sublist_other\">",
"       801",
"      </td>",
"      <td class=\"sublist_other\">",
"       114 (62)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Data for age and body mass index (BMI) are means (SD). Data are rounded to the nearest integer. CK is expressed as international units per liter.",
"    <div class=\"footnotes\">",
"     * Number (percentage) of participants with a CK above the ULN, as recommended by the manufacturer (140 IU/L for women, 174 IU/L for men; with appropriately established reference intervals, 2.5 percent of the subjects are expected to have values above the ULN).",
"     <br>",
"      &bull; Including participants of \"other\" ancestry (n = 68), with the exclusion of outliers (n = 3, 1 South Asian and 2 black participants) and those using statins (n = 30, 21 South Asian, 8 black participants, and 1 of other ancestry).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brewster, LM, Mairuhu, G, Sturk, A, van Montfrans, GA. Distribution of creatine kinase in the general population: Implications for statin therapy. Am Heart J 2007; 154:655. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37629=[""].join("\n");
var outline_f36_47_37629=null;
var title_f36_47_37630="Calculator: Body mass index for adults (Metric, Patient information)";
var content_f36_47_37630=[" <div id=\"disclaimer\">",
"  The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"  <a href=\"/home/terms-use\" target=\"_blank\">",
"   UpToDate Terms of Use",
"  </a>",
"  &copy;2013 UpToDate, Inc.",
" </div>",
" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BodyMassIndexPatient_Metric_form\" name=\"BodyMassIndexPatient_Metric_form\" onkeydown=\"clrResults();\" onkeyup=\"BodyMassIndexPatient_Metric_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Body mass index for adults (Metric, Patient information)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Body Mass Index (BMI) is a measure of weight in relation to height, and is  the most practical way to estimate if an individual is underweight, healthy  weight, overweight, or obese.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Enter height and weight:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"BodyMassIndexPatient_Metric_fx(); minMaxCheck();\" onchange=\"BodyMassIndexPatient_Metric_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"BodyMassIndexPatient_Metric_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"BodyMassIndexPatient_Metric_fx(); minMaxCheck();\" onchange=\"BodyMassIndexPatient_Metric_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"BodyMassIndexPatient_Metric_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              BMI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"BMI_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Body Mass Index Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &lt; 18.5:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Underweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &gt;= 18.5 and &lt; 25:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Healthy weight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &gt;= 25 and &lt; 30:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Overweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &gt;= 30:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Obesity",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults.",
"        <i>",
"         Bethesda: National Institutes of Health",
"        </i>",
"        . 2000, NIH publication 00-4084.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37630=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BodyMassIndexPatient_Metric_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BodyMassIndexPatient_Metric_form){",
"",
"",
"doCalc = true;",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 1;",
"BMI =  Weight / power(Height/100, 2);",
"",
"if (doCalc) BMI_param.value = fixDP(BMI, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (BMI < 18.5){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((BMI >= 18.5) && (BMI < 25)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((BMI >= 25) && (BMI < 30)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if (BMI >= 30){ document.getElementById('rr1_4').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexPatient_Metric_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexPatient_Metric_form){",
"",
"BMI_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f36_47_37630=null;
var title_f36_47_37631="Wagner grade 2 ulcer";
var content_f36_47_37631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wagner grade 2 ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foot from a diabetic patient with a penetrating neuropathic ulcer that is not associated with abscess formation or bone involvement (Wagner grade 2). The toes have been pulled anteriorly because the anterior tibial muscles are unopposed due to motor neuropathy-induced weakness of the intrinsic foot muscles. This promotes subluxation of the proximal interphalangeal-metatarsal joints, resulting in a claw toe appearance (arrow) and in increased pressure on the metatarsal heads, predisposing to ulcer formation at this site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_47_37631=[""].join("\n");
var outline_f36_47_37631=null;
